Article

Hilton, S., Naud, S., Caldwell, J. J., Boxall, K., Burns, S., Anderson, V. E., Antoni, L., Allen, C. E., Pearl, L. H., Oliver, A. W., Aherne, G. W., Garrett, M. D., Collins, I. (2010) Identification and characterisation of 2-aminopyridine inhibitors of checkpoint kinase 2. BIOORGANIC & MEDICINAL CHEMISTRY, 18 (2). pp. 707-718. ISSN 0968-0896

Dhomen, N., Dias, S. D. R., Hayward, R., Ogilvie, L., Hedley, D., Delmas, V., McCarthy, A., Henderson, D., Springer, C. J., Pritchard, C., Larue, L., Marais, R. (2010) Inducible expression of (V600E)Braf using tyrosinase-driven Cre recombinase results in embryonic lethality. PIGMENT CELL & MELANOMA RESEARCH, 23 (1). pp. 112-120. ISSN 1755-1471

Heidom, S. J., Milagre, C., Whittaker, S., Nourry, A., Niculescu-Duvas, I., Dhomen, N., Hussain, J., Reis-Filho, J. S., Springer, C. J., Pritchard, C., Marais, R. (2010) Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF. CELL, 140 (2). pp. 209-221. ISSN 0092-8674

Workman, P., van Montfort, R. L. M. (2010) PI(3) KINASES Revealing the delta lady. NATURE CHEMICAL BIOLOGY, 6 (2). pp. 82-83. ISSN 1552-4450

Walton, M. I., Eve, P. D., Hayes, A., Valenti, M., De Haven Brandon, A., Box, G., Boxall, K. J., Aherne, G. W., Eccles, S. A., Raynaud, F. I., Williams, D. H., Reader, J. C., Collins, I., Garrett, M. D. (2010) The preclinical pharmacology and therapeutic activity of the novel CHK1 inhibitor SAR-020106. MOLECULAR CANCER THERAPEUTICS, 9 (1). pp. 89-100. ISSN 1535-7163

Whelligan, D. K., Thomson, D. W., Taylor, D., Hoelder, S. (2010) Two-Step Synthesis of Aza- and Diazaindoles from Chloroamino-N-heterocycles Using Ethoxyvinylborolane. JOURNAL OF ORGANIC CHEMISTRY, 75 (1). pp. 11-15. ISSN 0022-3263

Le Cesne, A., Van Glabbeke, M., Verweij, J., Casali, P. G., Findlay, M., Reichardt, P., Issels, R., Judson, I., Schoffski, P., Leyvraz, S., Bui, B., Hogendoorn, P. C. W., Sciot, R., Blay, J. (2009) Absence of Progression As Assessed by Response Evaluation Criteria in Solid Tumors Predicts Survival in Advanced GI Stromal Tumors Treated With Imatinib Mesylate: The Intergroup EORTC-ISG-AGITG Phase III Trial. JOURNAL OF CLINICAL ONCOLOGY, 27 (24). pp. 3969-3974. ISSN 0732-183X

Gaspar, N., Sharp, S. Y., Pacey, S., Jones, C., Walton, M., Vassal, G., Eccles, S., Pearson, A., Workman, P. (2009) Acquired Resistance to 17-Allylamino-17-Demethoxygeldanamycin (17-AAG, Tanespimycin) in Glioblastoma Cells. CANCER RESEARCH, 69 (5). pp. 1966-1975. ISSN 0008-5472

Richards, M. W., O'Regan, L., Mas-Droux, C., Blot, J. M. Y., Cheung, J., Hoelder, S., Fry, A. M., Bayliss, R. (2009) An Autoinhibitory Tyrosine Motif in the Cell-Cycle-Regulated Nek7 Kinase Is Released through Binding of Nek9. MOLECULAR CELL, 36 (4). pp. 560-570. ISSN 1097-2765

Raynaud, F. I., Eccles, S. A., Patel, S., Alix, S., Box, G., Chuckowree, I., Folkes, A., Gowan, S., Brandon, A. D. H., Di Stefano, F., Hayes, A., Henley, A. T., Lensun, L., Pergl-Wilson, G., Robson, A., Saghir, N., Zhyvoloup, A., McDonald, E., Sheldrake, P., Shuttleworth, S., Valenti, M., Wan, N. C., Clarke, P. A., Workman, P. (2009) Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941. MOLECULAR CANCER THERAPEUTICS, 8 (7). pp. 1725-1738. ISSN 1535-7163

Harvey, A. J., Pennington, C. J., Porter, S., Burmi, R. S., Edwards, D. R., Court, W., Eccles, S. A., Crompton, M. R. (2009) Brk Protects Breast Cancer Cells from Autophagic Cell Death Induced by Loss of Anchorage. AMERICAN JOURNAL OF PATHOLOGY, 175 (3). pp. 1226-1234. ISSN 0002-9440

Bibby, R. A., Tang, C., Faisal, A., Drosopoulos, K., Lubbe, S., Houlston, R., Bayliss, R., Linardopoulos, S. (2009) A Cancer-associated Aurora A Mutant Is Mislocalized and Misregulated Due to Loss of Interaction with TPX2. JOURNAL OF BIOLOGICAL CHEMISTRY, 284 (48). pp. 33177-33184. ISSN 0021-9258

Beloueche-Babari, M., Peak, J. C., Jackson, L. E., Tiet, M. Y., Leach, M. O., Eccles, S. A. (2009) Changes in choline metabolism as potential biomarkers of phospholipase C gamma 1 inhibition in human prostate cancer cells. MOLECULAR CANCER THERAPEUTICS, 8 (5). pp. 1305-1311. ISSN 1535-7163

Brown, N. (2009) Chemoinformatics-An Introduction for Computer Scientists. ACM COMPUTING SURVEYS, 41 (2). ISSN 0360-0300

Postel-Vinay, S., Arkenau, H-T, Olmos, D., Ang, J., Barriuso, J., Ashley, S., Banerji, U., De-Bono, J., Judson, I., Kaye, S. (2009) Clinical benefit in Phase-I trials of novel molecularly targeted agents: does dose matter? BRITISH JOURNAL OF CANCER, 100 (9). pp. 1373-1378. ISSN 0007-0920

Arkenau, H. T., Brunetto, A. T., Barriuso, J., Olmos, D., Eaton, D., de Bono, J., Judson, I., Kaye, S. (2009) Clinical Benefit of New Targeted Agents in Phase I Trials in Patients with Advanced Colorectal Cancer. ONCOLOGY, 76 (3). pp. 151-156. ISSN 0030-2414

Brough, P. A., Barril, X., Borgognoni, J., Chene, P., Davies, N. G. M., Davis, B., Drysdale, M. J., Dymock, B., Eccles, S. A., Garcia-Echeverria, C., Fromont, C., Hayes, A., Hubbard, R. E., Jordan, A. M., Jensen, M. R., Massey, A., Merrett, A., Padfield, A., Parsons, R., Radimerski, T., Raynaud, F. I., Robertson, A., Roughley, S. D., Schoepfer, J., Simmonite, H., Sharp, S. Y., Surgenor, A., Valenti, M., Walls, S., Webb, P., Wood, M., Workman, P., Wright, L. (2009) Combining Hit Identification Strategies: Fragment-Based and in Silico Approaches to Orally Active 2-Aminothieno[2,3-d]pyrimidine Inhibitors of the Hsp90 Molecular Chaperone. JOURNAL OF MEDICINAL CHEMISTRY, 52 (15). pp. 4794-4809. ISSN 0022-2623

Pandher, R., Ducruix, C., Eccles, S. A., Raynaud, F. I. (2009) Cross-platform Q-TOF validation of global exo-metabolomic analysis: Application to human glioblastoma cells treated with the standard PI 3-Kinase inhibitor LY294002. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 877 (13). pp. 1352-1358. ISSN 1570-0232

Powers, M. V., Clarke, P. A., Workman, P. (2009) Death by chaperone HSP90, HSP70 or both? CELL CYCLE, 8 (4). pp. 518-526. ISSN 1538-4101

Torr, J. E., Large, J. M., McDonald, E. (2009) Design and Combinatorial Synthesis of a Library of Methylenesulfonamides and Related Compounds as Potential Kinase Inhibitors. COMBINATORIAL CHEMISTRY & HIGH THROUGHPUT SCREENING, 12 (3). pp. 275-284. ISSN 1386-2073

Andrews, M. D., Green, M. P., Allerton, C. M. N., Batchelor, D. V., Blagg, J., Brown, A. D., Gordon, D. W., McMurray, G., Millns, D. J., Nichols, C. L., Watson, L. (2009) Design and synthesis of piperazinylpyrimidinones as novel selective 5-HT2c agonists. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 19 (18). pp. 5346-5350. ISSN 0960-894X

Rogers, S. J., Box, C., Chambers, P., Barbachano, Y., Nutting, C. M., Rhys-Evans, P., Workman, P., Harrington, K. J., Eccles, S. A. (2009) Determinants of response to epidermal growth factor receptor tyrosine kinase inhibition in squamous cell carcinoma of the head and neck. JOURNAL OF PATHOLOGY, 218 (1). pp. 122-130. ISSN 0022-3417

Bax, D. A., Gaspar, N., Little, S. E., Marshall, L., Perryman, L., Regairaz, M., Viana-Pereira, M., Vuononvirta, R., Sharp, S. Y., Reis-Filho, J. S., Stavale, J. N., Al-Sarraj, S., Reis, R. M., Vassal, G., Pearson, A. D. J., Hargrave, D., Ellison, D. W., Workman, P., Jones, C. (2009) EGFRvIII Deletion Mutations in Pediatric High-Grade Glioma and Response to Targeted Therapy in Pediatric Glioma Cell Lines. CLINICAL CANCER RESEARCH, 15 (18). pp. 5753-5761. ISSN 1078-0432

Reid, A. H. M., Protheroe, A., Attard, G., Hayward, N., Vidal, L., Spicer, J., Shaw, H. M., Bone, E. A., Carter, J., Hooftman, L., Harris, A., De Bono, J. S. (2009) A First-in-Man Phase I and Pharmacokinetic Study on CHR-2797 (Tosedostat), an Inhibitor of M1 Aminopeptidases, in Patients with Advanced Solid Tumors. CLINICAL CANCER RESEARCH, 15 (15). pp. 4978-4985. ISSN 1078-0432

Carden, C. P., Banerji, U., Kaye, S. B., Workman, P., de Bono, J. S. (2009) From Darkness to Light With Biomarkers in Early Clinical Trials of Cancer Drugs. CLINICAL PHARMACOLOGY & THERAPEUTICS, 85 (2). pp. 131-133. ISSN 0009-9236

Berriman, M., Haas, B. J., LoVerde, P. T., Wilson, R. A., Dillon, G. P., Cerqueira, G. C., Mashiyama, S. T., Al-Lazikani, B., Andrade, L. F., Ashton, P. D., Aslett, M. A., Bartholomeu, D. C., Blandin, G., Caffrey, C. R., Coghlan, A., Coulson, R., Day, T. A., Delcher, A., DeMarco, R., Djikeng, A., Eyre, T., Gamble, J. A., Ghedin, E., Gu, Y., Hertz-Fowler, C., Hirai, H., Hirai, Y., Houston, R., Ivens, A., Johnston, D. A., Lacerda, D., Macedo, C. D., McVeigh, P., Ning, Z., Oliveira, G., Overington, J. P., Parkhill, J., Pertea, M., Pierce, R. J., Protasio, A. V., Quail, M. A., Rajandream, M., Rogers, J., Sajid, M., Salzberg, S. L., Stanke, M., Tivey, A. R., White, O., Williams, D. L., Wortman, J., Wu, W., Zamanian, M., Zerlotini, A., Fraser-Liggett, C. M., Barrell, B. G., El-Sayed, N. M. (2009) The genome of the blood fluke Schistosoma mansoni. NATURE, 460 (7253). pp. 352-365. ISSN 0028-0836

Garland, P. B., Serafinowski, P. J. (2009) High yield detritylation of surface-attached nucleosides with photoacid generated in an overlying solid film: roles of translational diffusion and scavenging. ORGANIC & BIOMOLECULAR CHEMISTRY, 7 (3). pp. 451-459. ISSN 1477-0520

Jamin, Y., Gabellieri, C., Smyth, L., Reynolds, S., Robinson, S. P., Springer, C. J., Leach, M. O., Payne, G. S., Eykyn, T. R. (2009) Hyperpolarized C-13 Magnetic Resonance Detection of Carboxypeptidase G2 Activity. MAGNETIC RESONANCE IN MEDICINE, 62 (5). pp. 1300-1304. ISSN 0740-3194

Matthews, T. P., Klair, S., Burns, S., Boxall, K., Cherry, M., Fisher, M., Westwood, I. M., Walton, M. I., McHardy, T., Cheung, K. M. J., Van Montfort, R., Williams, D., Aherne, G. W., Garrett, M. D., Reader, J., Collins, I. (2009) Identification of Inhibitors of Checkpoint Kinase 1 through Template Screening. JOURNAL OF MEDICINAL CHEMISTRY, 52 (15). pp. 4810-4819. ISSN 0022-2623

Reynisson, J., Court, W., O'Neill, C., Day, J., Patterson, L., McDonald, E., Workman, P., Katan, M., Eccles, S. A. (2009) The identification of novel PLC-gamma inhibitors using virtual high throughput screening. BIOORGANIC & MEDICINAL CHEMISTRY, 17 (8). pp. 3169-3176. ISSN 0968-0896

Westwood, I., Cheary, D. M., Baxter, J. E., Richards, M. W., van Montfort, R. L. M., Fry, A. M., Bayliss, R. (2009) Insights into the Conformational Variability and Regulation of Human Nek2 Kinase. JOURNAL OF MOLECULAR BIOLOGY, 386 (2). pp. 476-485. ISSN 0022-2836

Axerio-Cilies, P., Castaneda, I. P., Mirza, A., Reynisson, J. (2009) Investigation of the incidence of "undesirable" molecular moieties for high-throughput screening compound libraries in marketed drug compounds. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 44 (3). pp. 1128-1134. ISSN 0223-5234

Mirza, A., Desai, R., Reynisson, J. (2009) Known drug space as a metric in exploring the boundaries of drug-like chemical space. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 44 (12). pp. 5006-5011. ISSN 0223-5234

Quevedo, C. E., Bavetsias, V., McDonald, E. (2009) Microwave-assisted synthesis of 2-aminonicotinic acids by reacting 2-chloronicotinic acid with amines. TETRAHEDRON LETTERS, 50 (21). pp. 2481-2483. ISSN 0040-4039

Bax, D. A., Little, S. E., Gaspar, N., Perryman, L., Marshall, L., Viana-Pereira, M., Jones, T. A., Williams, R. D., Grigoriadis, A., Vassal, G., Workman, P., Sheer, D., Reis, R. M., Pearson, A. D. J., Hargrave, D., Jones, C. (2009) Molecular and Phenotypic Characterisation of Paediatric Glioma Cell Lines as Models for Preclinical Drug Development. PLOS ONE, 4 (4). ISSN 1932-6203

Guillard, S., Clarke, P. A., Poele, R. T., Mohri, Z., Bjerke, L., Valenti, M., Raynaud, F., Eccles, S. A., Workman, P. (2009) Molecular pharmacology of phosphatidylinositol 3-kinase inhibition in human glioma. CELL CYCLE, 8 (3). pp. 443-453. ISSN 1538-4101

Menard, D., Niculescu-Duvaz, I., Dijkstra, H. P., Niculescu-Duvaz, D., Suijkerbuijk, B. M. J. M., Zambon, A., Nourry, A., Roman, E., Davies, L., Marine, H. A., Friedlos, F., Kirk, R., Whittaker, S., Gill, A., Taylor, R. D., Marais, R., Springer, C. J. (2009) Novel Potent BRAF Inhibitors: Toward 1 nM Compounds through Optimization of the Central Phenyl Ring. JOURNAL OF MEDICINAL CHEMISTRY, 52 (13). pp. 3881-3891. ISSN 0022-2623

Mancini, L., Davies, L., Friedlos, F., Falck-Miniotis, M., Dzik-Jurasz, A. S., Springer, C. J., Leach, M. O., Payne, G. S. (2009) A novel technique to monitor carboxypeptidase G2 expression in suicide gene therapy using F-19 magnetic resonance spectroscopy. NMR IN BIOMEDICINE, 22 (5). pp. 561-566. ISSN 0952-3480

Constantinidou, A., Jones, R. L., Scurr, M., Al-Muderis, O., Judson, I. (2009) Pegylated liposomal doxorubicin, an effective, well-tolerated treatment for refractory aggressive fibromatosis. EUROPEAN JOURNAL OF CANCER, 45 (17). pp. 2930-2934. ISSN 0959-8049

Baird, R. D., Kitzen, J., Clarke, P. A., Planting, A., Reade, S., Reid, A., Welsh, L., Lopez Lazaro, L., de las Heras, B., Judson, I. R., Kaye, S. B., Eskens, F., Workman, P., deBono, J. S., Verweij, J. (2009) Phase I safety, pharmacokinetic, and pharmacogenomic trail of ES-285, a novel marine cytotoxic agent, administered to adult patients with advanced solid tumors. MOLECULAR CANCER THERAPEUTICS, 8 (6). pp. 1430-1437. ISSN 1535-7163

Plummer, R., Vidal, L., Griffin, M., Lesley, M., de Bono, J., Coulthard, S., Sludden, J., Siu, L.L., Chen, E.X., Oza, A.M., Reid, G.K., McLeod, A.R., Besterman, J.M., Lee, C., Judson, I., Calvert, H., Bloody, A.V. (2009) Phase I Study of MG98, an Oligonucleotide Antisense Inhibitor of Human DNA Methyltransferase 1, Given as a 7-Day Infusion in Patients with Advanced Solid Tumors. CLINICAL CANCER RESEARCH, 15 (9). pp. 3177-3183. ISSN 1078-0432

Lee, C. P., Payne, G. S., Oregioni, A., Ruddle, R., Tan, S., Raynaud, F. I., Eaton, D., Campbell, M. J., Cross, K., Halbert, G., Tracy, M., McNamara, J., Seddon, B., Leach, M. O., Workman, P., Judson, I. (2009) A phase I study of the nitroimidazole hypoxia marker SR4554 using F-19 magnetic resonance spectroscopy. BRITISH JOURNAL OF CANCER, 101 (11). pp. 1860-1868. ISSN 0007-0920

Arkenau, H. T., Barriuso, J., Olmos, D., Ang, J. E., de Bono, J., Judson, I., Kaye, S. (2009) Prospective Validation of a Prognostic Score to Improve Patient Selection for Oncology Phase I Trials. JOURNAL OF CLINICAL ONCOLOGY, 27 (16). pp. 2692-2696. ISSN 0732-183X

Niculescu-Duvaz, D., Gaulon, C., Dijkstra, H. P., Niculescu-Duvaz, I., Zambon, A., Menard, D., Suijkerbuijk, Bmjm, Nourry, A., Davies, L., Manne, H., Friedlos, F., Ogilvie, L., Hedley, D., Whittaker, S., Kirk, R., Gill, A., Taylor, R. D., Raynaud, F. I., Moreno-Farre, J., Marais, R., Springer, C. J. (2009) Pyridoimidazolones as Novel Potent Inhibitors of v-Raf Murine Sarcoma Viral Oncogene Homologue B1 (BRAF). JOURNAL OF MEDICINAL CHEMISTRY, 52 (8). pp. 2255-2264. ISSN 0022-2623

Proisy, N., Taylor, S., Nelson, A., Collins, I. (2009) Rapid Synthesis of 3-Aminoisoquinoline-5-sulfonamides Using the Buchwald-Hartwig Reaction. SYNTHESIS-STUTTGART (4). pp. 561-566. ISSN 0039-7881

Koh, D., Blackledge, M., Collins, D. J., Padhani, A. R., Wallace, T., Wilton, B., Taylor, N. J., Stirling, J. J., Sinha, R., Walicke, P., Leach, M. O., Judson, I., Nathan, P. (2009) Reproducibility and changes in the apparent diffusion coefficients of solid tumours treated with combretastatin A4 phosphate and bevacizumab in a two-centre phase I clinical trial. EUROPEAN RADIOLOGY, 19 (11). pp. 2728-2738. ISSN 0938-7994

Smith, J. R., Clarke, P. A., de Billy, E., Workman, P. (2009) Silencing the cochaperone CDC37 destabilizes kinase clients and sensitizes cancer cells to HSP90 inhibitors. ONCOGENE, 28 (2). pp. 157-169. ISSN 0950-9232

Yang, J., Ahmed, A., Poon, E., Perusinghe, N., Brandon, A. D., Box, G., Valenti, M., Eccles, S., Rouschop, K., Wouters, B., Ashcroft, M. (2009) Small-Molecule Activation of p53 Blocks Hypoxia-Inducible Factor 1 alpha and Vascular Endothelial Growth Factor Expression In Vivo and Leads to Tumor Cell Apoptosis in Normoxia and Hypoxia. MOLECULAR AND CELLULAR BIOLOGY, 29 (8). pp. 2243-2253. ISSN 0270-7306

Prodromou, C., Nuttall, J. M., Millson, S. H., Roe, S. M., Sim, T. S., Tan, D., Workman, P., Pearl, L. H., Piper, P. W. (2009) Structural Basis of the Radicicol Resistance Displayed by a Fungal Hsp90. ACS CHEMICAL BIOLOGY, 4 (4). pp. 289-297. ISSN 1554-8929

Gorsuch, S., Bavetsias, V., Rowlands, M. G., Aherne, G. W., Workman, P., Jarman, M., McDonald, E. (2009) Synthesis of isothiazol-3-one derivatives as inhibitors of histone acetyltransferases (HATs). BIOORGANIC & MEDICINAL CHEMISTRY, 17 (2). pp. 467-474. ISSN 0968-0896

Sarker, D., Reid, A. H. M., Yap, T. A., de Bono, J. S. (2009) Targeting the PI3K/AKT Pathway for the Treatment of Prostate Cancer. CLINICAL CANCER RESEARCH, 15 (15). pp. 4799-4805. ISSN 1078-0432

McDonald, E. (2009) Vitamins and cofactors: highlights of ESBOC 2009. NATURE CHEMICAL BIOLOGY, 5 (8). pp. 530-533. ISSN 1552-4450

Brough, P. A., Aherne, W., Barril, X., Borgognoni, J., Boxall, K., Cansfield, J. E., Cheung, K. M. J., Collins, I., Davies, N. G. M., Drysdale, M. J., Dymock, B., Eccles, S. A., Finch, H., Fink, A., Hayes, A., Howes, R., Hubbard, R. E., James, K., Jordan, A. M., Lockie, A., Martins, V., Massey, A., Matthews, T. P., McDonald, E., Northfield, C. J., Pearl, L. H., Prodromou, C., Ray, S., Raynaud, F. I., Roughley, S. D., Sharp, S. Y., Surgenor, A., Walmsley, D. L., Webb, P., Wood, M., Workman, P., Wrightt, L. (2008) 4,5-diarylisoxazole HSP90 chaperone inhibitors: Potential therapeutic agents for the treatment of cancer. JOURNAL OF MEDICINAL CHEMISTRY, 51 (2). pp. 196-218. ISSN 0022-2623

Arkenau, H. T., Olmos, D., Ang, J. E., Barriuso, J., Karauasilis, V., Ashley, S., de Bono, J., Judson, I., Kaye, S. (2008) 90-Days mortality rate in patients treated within the context of a phase-I trial: How should we identify patients who should not go on trial? EUROPEAN JOURNAL OF CANCER, 44 (11). pp. 1536-1540. ISSN 0959-8049

Friedlos, F., Lehouritis, P., Ogilvie, L., Hedley, D., Davies, L., Bermudes, D., King, I., Martin, J., Marais, R., Springer, C. J. (2008) Attenuated Salmonella targets prodrug activating enzyme carboxypeptidase G2 to mouse melanoma and human breast and colon carcinomas for effective suicide gene therapy. CLINICAL CANCER RESEARCH, 14 (13). pp. 4259-4266. ISSN 1078-0432

Ioakimidis, L., Thoukydidis, L., Mirza, A., Naeem, S., Reynisson, J. (2008) Benchmarking the reliability of QikProp. Correlation between experimental and predicted values. QSAR & COMBINATORIAL SCIENCE, 27 (4). pp. 445-456. ISSN 1611-020X

Banerji, U., Affolter, A., Judson, I., Marais, R., Workman, P. (2008) BRAF and NRAS mutations in melanoma: potential relationships to clinical response to HSP90 inhibitors. MOLECULAR CANCER THERAPEUTICS, 7 (4). pp. 737-739. ISSN 1535-7163

Rayter, S., Elliott, R., Travers, J., Rowlands, M. G., Richardson, T. B., Boxall, K., Jones, K., Linardopoulos, S., Workman, P., Aherne, W., Lord, C. J., Ashworth, A. (2008) A chemical inhibitor of PPM1D that selectively kills cells overexpressing PPM1D. ONCOGENE, 27 (8). pp. 1036-1044. ISSN 0950-9232

Krige, D., Needham, L. A., Bawden, L. J., Flores, N., Farmer, H., Miles, L. E. C., Stone, E., Callaghan, J., Chandler, S., Clark, V. L., Kirwin-Jones, P., Legris, V., Owen, J., Patel, T., Wood, S., Box, G., Laber, D., Odedra, R., Wright, A., Wood, L. M., Eccles, S. A., Bone, E. A., Ayscough, A., Drummond, A. H. (2008) CHR-2797: An antiproliferative aminopeptidase inhibitor that leads to amino acid deprivation in human leukemic cells. CANCER RESEARCH, 68 (16). pp. 6669-6679. ISSN 0008-5472

Burton, J. W., Anderson, E. A., O'Sullivan, P. T., Collins, I., Davies, J. E., Bond, A. D., Feeder, N., Holmes, A. B. (2008) The Claisen rearrangement approach to fused bicyclic medium-ring oxacycles. ORGANIC & BIOMOLECULAR CHEMISTRY, 6 (4). pp. 693-702. ISSN 1477-0520

Arkenau, H. T., Olmos, D., Ang, J. E., de Bono, J., Judson, I., Kaye, S. (2008) Clinical outcome and prognostic factors for patients treated within the context of a phase I study: the Royal Marsden Hospital experience. BRITISH JOURNAL OF CANCER, 98 (6). pp. 1029-1033. ISSN 0007-0920

Gutierrez, C. D., Bavetsias, V., McDonald, E. (2008) ClTi((OPr)-Pr-i)(3)-promoted reductive amination on the solid phase: Combinatorial synthesis of a biaryl-based sulfonamide library. JOURNAL OF COMBINATORIAL CHEMISTRY, 10 (2). pp. 280-284. ISSN 1520-4766

Tabernero, J., Rojo, F., Calvo, E., Burris, H., Judson, I., Hazell, K., Martinelli, E., Cajal, S. R. Y., Jones, S., Vidal, L., Shand, N., Macarulla, T., Ramos, F. J., Dimitrijevic, S., Zoellner, U., Tang, P., Stumm, M., Lane, H. A., Lebwohl, D., Baselga, J. (2008) Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: A phase I tumor pharmacodynamic study in patients with advanced solid tumors. JOURNAL OF CLINICAL ONCOLOGY, 26 (10). pp. 1603-1610. ISSN 0732-183X

Powers, M. V., Clarke, P. A., Workman, P. (2008) Dual targeting of HSC70 and HSP72 inhibits HSP90 function and induces tumor-specific apoptosis. CANCER CELL, 14 (3). pp. 250-262. ISSN 1535-6108

van Erp, N., Gelderblom, H., Van Glabbeke, M., Van Oosterorn, A., Verweij, J., Guchelaar, H. J., Debiec-Rychter, M., Peng, B., Blay, J. Y., Judson, I. (2008) Effect of Cigarette Smoking on Imatinib in Patients in the Soft Tissue and Bone Sarcoma Group of the EORTC. CLINICAL CANCER RESEARCH, 14 (24). pp. 8308-8313. ISSN 1078-0432

Kalusa, A., Chessum, N., Jones, K. (2008) An efficient synthesis of 2,3-diaryl (3H)-quinazolin-4-ones via imidoyl chlorides. TETRAHEDRON LETTERS, 49 (41). pp. 5840-5842. ISSN 0040-4039

Carden, C. P., Agarwal, R., Saran, F., Judson, I. R. (2008) Eligibility of patients with brain metastases for phase I trials: time for a rethink? LANCET ONCOLOGY, 9 (10). pp. 1012-1017. ISSN 1470-2045

Drilon, A. D., Popat, S., Bhuchar, G., D'Adamo, D. R., Keohan, M. L., Fisher, C., Antonescu, C. R., Singer, S., Brennan, M. F., Judson, I., Maki, R. G. (2008) Extraskeletal Myxoid Chondrosarcoma A Retrospective Review From 2 Referral Centers Emphasizing Long-term Outcomes With Surgery and Chemotherapy. CA-A CANCER JOURNAL FOR CLINICIANS, 113 (12). pp. 3364-3371. ISSN 0007-9235

Vaughan, C. K., Mollapour, M., Smith, J. R., Truman, A., Hu, B., Good, V. M., Panaretou, B., Neckers, L., Clarke, P. A., Workman, P., Piper, P. W., Prodrornou, C., Pearl, L. H. (2008) Hsp90-dependent activation of protein kinases is regulated by chaperone-targeted dephosphorylation of Cdc37. MOLECULAR CELL, 31 (6). pp. 886-895. ISSN 1097-2765

Folkes, A. J., Ahmadi, K., Alderton, W. K., Alix, S., Baker, S. J., Box, G., Chuckowree, I. S., Clarke, P. A., Depledge, P., Eccles, S. A., Friedman, L. S., Hayes, A., Hancox, T. C., Kugendradas, A., Lensun, L., Moore, P., Olivero, A. G., Pang, J., Patel, S., Pergl-Wilson, G. H., Raynaud, F. I., Robson, A., Saghir, N., Salphati, L., Sohal, S., Ultsch, M. H., Valenti, M., Wallweber, H. J. A., Wan, N. C., Wiesmann, C., Workman, P., Zhyvoloup, A., Zvelebil, M. J., Shuttleworth, S. J. (2008) The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer. JOURNAL OF MEDICINAL CHEMISTRY, 51 (18). pp. 5522-5532. ISSN 0022-2623

Caldwell, J. J., Davies, T. G., Doiiald, A. R. R., McHardy, T., Rowlands, M. G., Aherne, G. W., Hlinter, L. K., Taylor, K., Ruddle, R., Raynaud, F. I., Verdonk, M., Workman, P., Garrett, M. D., Collins, I. (2008) Identification of 4-(4-aminopiperidin-1-yl)-7H-pyrrolo[2,3-d]pyrimidines as selective inhibitors of protein kinase B through fragment elaboration. JOURNAL OF MEDICINAL CHEMISTRY, 51 (7). pp. 2147-2157. ISSN 0022-2623

Karavasilis, V., Digue, L., Arkenau, T., Eaton, D., Stapleton, S., de Bono, J., Judson, I., Kaye, S. (2008) Identification of factors limiting patient recruitment into phase I trials: A study from the Royal Marsden Hospital. EUROPEAN JOURNAL OF CANCER, 44 (7). pp. 978-982. ISSN 0959-8049

Banerji, U., Sain, N., Sharp, S. Y., Valenti, M., Asad, Y., Ruddle, R., Raynaud, F., Walton, M., Eccles, S. A., Judson, I., Jackman, A. L., Workman, P. (2008) An in vitro and in vivo study of the combination of the heat shock protein inhibitor 17-allylamino-17-demethoxygeldanamycin and carboplatin in human ovarian cancer models. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 62 (5). pp. 769-778. ISSN 0344-5704

Niculescu-Duvaz, D., Getaz, J., Springer, C. J. (2008) Long functionalized poly(ethylene glycol)s of defined molecular weight: Synthesis and application in solid-phase synthesis of conjugates. BIOCONJUGATE CHEMISTRY, 19 (4). pp. 973-981. ISSN 1043-1802

Bradshaw, T. D., Stone, E. L., Trapani, V., Leong, C. O., Matthews, C. S., Poele, R. T., Stevens, M. F. G. (2008) Mechanisms of acquired resistance to 2-(4-Amino-3-methylphenyl)benzothiazole in breast cancer cell lines. BREAST CANCER RESEARCH AND TREATMENT, 110 (1). pp. 57-68. ISSN 0167-6806

Lujambio, A., Calin, G. A., Villanueva, A., Ropero, S., Sanchez-Cespedes, M., Blanco, D., Montuenga, L. M., Rossi, S., Nicoloso, M. S., Faller, W. J., Gallagher, W. M., Eccles, S. A., Croce, C. M., Esteller, M. (2008) A microRNA DNA methylation signature for human cancer metastasis. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 105 (36). pp. 13556-13561. ISSN 0027-8424

Leyton, J., Smith, G., Lees, M., Perumal, M., Nguyen, Q. D., Aigbirhio, F. I., Golovko, O., He, Q. M., Workman, P., Aboagye, E. O. (2008) Noninvasive imaging of cell proliferation following mitogenic extracellular kinase inhibition by PD0325901. MOLECULAR CANCER THERAPEUTICS, 7 (9). pp. 3112-3121. ISSN 1535-7163

Chung, Y. L., Troy, H., Kristeleit, R., Aherne, W., Jackson, E., Atadja, P., Griffiths, J. R., Judson, I. R., Workman, P., Leach, M. O., Beloueche-Babari, M. (2008) Noninvasive magnetic resonance spectroscopic pharmacodynamic markers of a novel histone deacetylase inhibitor, LAQ824, in human colon carcinoma cells and xenografts. NEOPLASIA, 10 (4). pp. 303-313. ISSN 1522-8002

Niculescu-Duvaz, I., Roman, E., Whittaker, S. R., Friedlos, F., Kirk, R., Scanlon, I. J., Davies, L. C., Niculescu-Duvaz, D., Marais, R., Springer, C. J. (2008) Novel inhibitors of the v-raf murine sarcoma viral oncogene homologue B1 (BRAF) based on a 2,6-disubstituted pyrazine scaffold. JOURNAL OF MEDICINAL CHEMISTRY, 51 (11). pp. 3261-3274. ISSN 0022-2623

Eccles, S. A., Massey, A., Raynaud, F. I., Sharp, S. Y., Box, G., Valenti, M., Patterson, L., Brandon, A. D., Gowan, S., Boxall, F., Aherne, W., Rowlands, M., Hayes, A., Martins, V., Urban, F., Boxall, K., Prodromou, C., Pearl, L., James, K., Matthews, T. P., Cheung, K. M., Kalusa, A., Jones, K., McDonald, E., Barril, X., Brough, P. A., Cansfield, J. E., Dymock, B., Drysdale, M. J., Finch, H., Howes, R., Hubbard, R. E., Surgenor, A., Webb, P., Wood, M., Wright, L., Workman, P. (2008) NVP-AUY922: A novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis. CANCER RESEARCH, 68 (8). pp. 2850-2860. ISSN 0008-5472

Ashworth, A., Balkwill, F., Bast, R. C., Berek, J. S., Kaye, A., Boyd, J. A., Mills, G., Weinstein, J. N., Woolley, K., Workman, P. (2008) Opportunities and challenges in ovarian cancer research, a perspective from the 11th Ovarian cancer action/HHMT Forum, Lake Como, March 2007. GYNECOLOGIC ONCOLOGY, 108 (3). pp. 652-657. ISSN 0090-8258

Schlemmer, M., Reichardt, P., Verweij, J., Hartmann, J. T., Judson, I., Thyss, A., Hogendoorn, P. C. W., Marreaud, S., Van Glabbeke, M., Blay, J. Y. (2008) Paclitaxel in patients with advanced angiosarcomas of soft tissue: A retrospective study of the EORTC soft tissue and bone sarcoma group. EUROPEAN JOURNAL OF CANCER, 44 (16). pp. 2433-2436. ISSN 0959-8049

de Bono, J. S., Kristeleit, R., Tolcher, A., Fong, P., Pacey, S., Karavasilis, V., Mita, M., Shaw, H., Workman, P., Kaye, S., Rowinsky, E. K., Aherne, W., Atadja, P., Scott, J. W., Patnaik, A. (2008) Phase I Pharmacokineitic and Pharmacodynamic Study of LAQ824, a Hydroxamate Histone Deacetylase Inhibitor with a Heat Shock Protein-90 Inhibitory Profile, in Patients with Advanced Solid Tumors. CLINICAL CANCER RESEARCH, 14 (20). pp. 6663-6673. ISSN 1078-0432

O'Donnell, A., Faivre, S., Burris, H. A., Rea, D., Papadimitrakopoulou, V., Shand, N., Lane, H. A., Hazell, K., Zoellner, U., Kovarik, J. M., Brock, C., Jones, S., Raymond, E., Judson, I. (2008) Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. JOURNAL OF CLINICAL ONCOLOGY, 26 (10). pp. 1588-1595. ISSN 0732-183X

Sarker, D., Molife, R., Evans, T. R. J., Hardie, M., Marriott, C., Butzberger-Zimmerli, P., Morrison, R., Fox, J. A., Heise, C., Louie, S., Aziz, N., Garzon, F., Michelson, G., Judson, I. R., Jadayel, D., Braendle, E., de Bono, J. S. (2008) A phase I pharmacokinetic and pharmacodynamic study of TKI258, an oral, multitargeted receptor tyrosine kinase inhibitor in patients with advanced solid tumors. CLINICAL CANCER RESEARCH, 14 (7). pp. 2075-2081. ISSN 1078-0432

Peak, J. C., Jones, N. P., Hobbs, S., Katan, M., Eccles, S. A. (2008) Phospholipase C gamma 1 regulates the Rap GEF1-Rap1 signalling axis in the control of human prostate carcinoma cell adhesion. ONCOGENE, 27 (20). pp. 2823-2832. ISSN 0950-9232

Martin, N. G., McAndrew, P. C., Eve, P. D., Garrett, M. D. (2008) Phosphorylation of cyclin dependent kinase 4 on tyrosine 17 is mediated by Src family kinases. FEBS Journal, 275 (12). pp. 3099-3109. ISSN 1742-464X

Hughes, J. D., Blagg, J., Price, D. A., Bailey, S., DeCrescenzo, G. A., Devraj, R. V., Ellsworth, E., Fobian, Y. M., Gibbs, M. E., Gilles, R. W., Greene, N., Huang, E., Krieger-Burke, T., Loesel, J., Wager, T., Whiteley, L., Zhang, Y. (2008) Physiochemical drug properties associated with in vivo toxicological outcomes. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 18 (17). pp. 4872-4875. ISSN 0960-894X

Carroll, V. A., Ashcroft, M. (2008) Regulation of angiogenic factors by HDM2 in renal cell carcinoma. CANCER RESEARCH, 68 (2). pp. 545-552. ISSN 0008-5472

Jefferies, H. B. J., Cooke, F. T., Jat, P., Boucheron, C., Koizumi, T., Hayakawa, M., Kaizawa, H., Ohishi, T., Workman, P., Waterfield, M. D., Parker, P. J. (2008) A selective PIKfyve inhibitor blocks PtdIns(3,5) P-2 production and disrupts endomembrane transport and retroviral budding. EMBO REPORTS, 9 (2). pp. 164-170. ISSN 1469-221X

Holmes, J. L., Sharp, S. Y., Hobbs, S., Workman, P. (2008) Silencing of HSP90 cochaperone AHA1 expression decreases client protein activation and increases cellular sensitivity to the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin. CANCER RESEARCH, 68 (4). pp. 1188-1197. ISSN 0008-5472

Judson, I. (2008) State-of-the-art approach in selective curable tumours: soft tissue sarcoma. ANNALS OF ONCOLOGY, 19 (Supplement 7). pp. 166-169. ISSN 0923-7534

Serafinowski, P. J., Garland, P. B. (2008) Substituted 2-nitrobenzyltrichloroacetate esters for photodirected oligonucleotide detritylation in solid films. ORGANIC & BIOMOLECULAR CHEMISTRY, 6 (18). pp. 3284-3291. ISSN 1477-0520

Knight, J. F., Shepherd, C. J., Rizzo, S., Brewer, D., Jhavar, S., Dodson, A. R., Cooper, C. S., Eeles, R., Falconer, A., Kovacs, G., Garrett, M. D., Norman, A. R., Shipley, J., Hudson, D. L. (2008) TEAD1 and c-Cbl are novel prostate basal cell markers that correlate with poor clinical outcome in prostate cancer. BRITISH JOURNAL OF CANCER, 99 (11). pp. 1849-1858. ISSN 0007-0920

Murray, M., Hatcher, H., Jessop, F., Williams, D., Carroll, N., Bulusu, R., Judson, I. (2008) Treatment of wild-type gastrointestinal stromal tumor (WT-GIST) with imatinib and sunitinib. PEDIATRIC BLOOD & CANCER, 50 (2). pp. 386-388. ISSN 1545-5009

Judson, I., Demetri, G. (2007) Advances in the treatment of gastrointestinal stromal tumours. ANNALS OF ONCOLOGY, 18 (Supplement 10). pp. 20-24. ISSN 0923-7534

Hockley, S. L., Arlt, V. M., Brewer, D., te Poele, R., Workman, P., Giddings, I., Phillips, D. H. (2007) AHR- and DNA-damage-mediated gene expression responses induced by benzo(a)pyrene in human cell lines. CHEMICAL RESEARCH IN TOXICOLOGY, 20 (12). pp. 1797-1810. ISSN 0893-228X

Gowan, S. M., Hardcastle, A., Hallsworth, A. E., Valenti, M. R., Hunter, L. J. K., Brandon, A. K. D., Garrett, M. D., Raynaud, F., Workman, P., Aherne, W., Eccles, S. A. (2007) Application of meso scale technology for the measurement of phosphoproteins in human tumor xenografts. ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES, 5 (3). pp. 391-401. ISSN 1540-658X

Sun, C. B., Chan, F., Briassouli, P., Linardopoulos, S. (2007) Aurora kinase inhibition downregulates NF-kappa B and sensitises tumour cells to chemotherapeutic agents. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 352 (1). pp. 220-225. ISSN 0006-291X

Briassouli, P., Chan, F., Savage, K., Reis-Filho, J. S., Linardopoulos, S. (2007) Aurora-A regulation of nuclear factor-kappa B signaling by phosphorylation of I kappa B alpha. CANCER RESEARCH, 67 (4). pp. 1689-1695. ISSN 0008-5472

Witham, J., Valenti, M. R., De-Haven-Brandon, A. K., Vidot, S., Eccles, S. A., Kaye, S. B., Richardson, A. (2007) The Bcl-2/Bcl-X-L family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin. CLINICAL CANCER RESEARCH, 13 (23). pp. 7191-7198. ISSN 1078-0432

Leahy, M., Ray-Coquard, I., Verweij, J., Le Cesne, A., Duffaud, F., Hogendoorn, P. C. W., Fowst, C., de Balincourt, C., di Paola, E. D., van Glabbeke, M., Judson, I., Blay, J. Y. (2007) Brostallicin, an agent with potential activity in metastatic soft tissue sarcoma: A phase II study from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. EUROPEAN JOURNAL OF CANCER, 43 (2). pp. 308-315. ISSN 0959-8049

Gallo, D., Jacquemotte, F., Cleeren, A., Laios, I., Hadiy, S., Rowlands, M. G., Caille, O., Nonclercq, D., Laurent, G., Jacquot, Y., Leclercq, G. (2007) Calmodulin-independent, agonistic properties of a peptide containing the calmodulin binding site of estrogen receptor alpha. MOLECULAR AND CELLULAR ENDOCRINOLOGY, 268 (1-2). pp. 37-49. ISSN 0303-7207

Torr, J. E., Large, J. M., McDonald, E. (2007) A convenient one-pot preparation and applications of high loading benzhydrylamine solid phase linkers. TETRAHEDRON LETTERS, 48 (11). pp. 1951-1954. ISSN 0040-4039

Whittaker, S. R., Poele, R. H. T., Chan, F., Linardopoulos, S., Walton, M. I., Garrett, M. D., Workman, P. (2007) The cyclin-dependent kinase inhibitor seliciclib (Rroscovitine; CYC202) decreases the expression of mitotic control genes and prevents entry into mitosis. CELL CYCLE, 6 (24). pp. 3114-3131. ISSN 1538-4101

Bavetsias, V., Henderson, E.A., McDonald, E. (2007) Cyclopenta[g]quinazolinone-based inhibitors of thymidylate synthase targeting alpha-folate receptor overexpressing tumours: synthetic approaches to 4-{N-[(6RS)-2-hydroxymethyl-4-oxo-3,4,7,8-tetrahydro-6H-cyclopenta[g]quinazolin-6-yl]-N-(prop-2-ynyl)amino}benzoic acid. TETRAHEDRON, 63 (7). pp. 1537-1543. ISSN 0040-4020

Smyth, L. A., Matthews, T. P., Horton, P. N., Hursthouse, M. B., Collins, I. (2007) Divergent cyclisations of 2-(5-amino-4-carbamoyl-1H-pyrazol-3-yl) acetic acids with formyl and acetyl electrophiles. TETRAHEDRON, 63 (39). pp. 9627-9634. ISSN 0040-4020

Reid, A., Vidal, L., Shaw, H., de Bono, J. (2007) Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu). EUROPEAN JOURNAL OF CANCER, 43 (3). pp. 481-489. ISSN 0959-8049

Hardcastle, A., Tomlin, P., Norris, C., Richards, J., Cordwell, M., Boxall, K., Rowlands, M., Jones, K., Collins, I., McDonald, E., Workman, P., Aherne, W. (2007) A duplexed phenotypic screen for the simultaneous detection of inhibitors of the molecular chaperone heat shock protein 90 and modulators of cellular acetylation. MOLECULAR CANCER THERAPEUTICS, 6 (3). pp. 1112-1122. ISSN 1535-7163

Grosso, F., Jones, R. L., Demetri, G. D., Judson, I. R., Blay, J. Y., Le Cesne, A., Sanfilippo, R., Casieri, P., Collini, P., Dileo, P., Spreafico, C., Stacchiotti, S., Tamborini, E., Tercero, J. C., Jimeno, J., D'Incalci, M., Gronchi, A., Fletcher, J. A., Pilotti, S., Casali, P. G. (2007) Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. LANCET ONCOLOGY, 8 (7). pp. 595-602. ISSN 1470-2045

Pitkin, L., Luangdilok, S., Corbishley, C., Wilson, P. O. G., Dalton, P., Bray, D., Mady, S., Williamson, P., Odutoye, T., Evans, P. R., Syrigos, K. N., Nutting, C. M., Barbachano, Y., Eccles, S., Harrington, K. J. (2007) Expression of CC chemokine receptor 7 in tonsillar cancer predicts cervical nodal metastasis, systemic relapse and survival. BRITISH JOURNAL OF CANCER, 97 (5). pp. 670-677. ISSN 0007-0920

Saturno, G., Pesenti, M., Cavazzoli, C., Rossi, A., Giusti, A. M., Gierke, B., Pawlak, M., Venturi, M. (2007) Expression of serine/threonine protein-kinases and related factors in normal monkey and human retinas: The mechanistic understanding of a CDK2 inhibitor induced retinal toxicity. TOXICOLOGIC PATHOLOGY, 35 (7). pp. 972-983. ISSN 0192-6233

Maloney, A., Clarke, P. A., Naaby-Hansen, S., Stein, R., Koopman, J. O., Akpan, A., Yang, A., Zvelebil, M., Cramer, R., Stimson, L., Aherne, W., Banerji, U., Judson, I., Sharp, S., Powers, M., deBilly, E., Salmons, J., Walton, M., Burlingame, A., Waterfield, M., Workman, P. (2007) Gene and protein expression profiling of human ovarian cancer cells treated with the heat shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin. CANCER RESEARCH, 67 (7). pp. 3239-3253. ISSN 0008-5472

Davenport, E. L., Moore, H. E., Dunlop, A. S., Sharp, S. Y., Workman, P., Morgan, G. J., Davies, F. E. (2007) Heat shock protein inhibition is associated with activation of the unfolded protein response pathway in myeloma plasma cells. BLOOD, 110 (7). pp. 2641-2649. ISSN 0006-4971

Bavetsias, V., Sun, C., Bouloc, N., Reynisson, J., Workman, P., Linardopoulos, S., McDonald, E. (2007) Hit generation and exploration: Imidazo[4,5-b] pyridine derivatives as inhibitors of Aurora kinases. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 17 (23). pp. 6567-6571. ISSN 0960-894X

Saxty, G., Woodhead, S. J., Berdini, V., Davies, T. G., Verdonk, M. L., Wyatt, P. G., Boyle, R. G., Barford, D., Downham, R., Garrett, M. D., Carr, R. A. (2007) Identification of Inhibitors of Protein Kinase B Using Fragment-Based Lead Discovery. JOURNAL OF MEDICINAL CHEMISTRY, 50 (10). pp. 2293-2296. ISSN 0022-2623

Verweij, J., Casali, P. G., Kotasek, D., Le Cesne, A., Reichard, P., Judson, I. R., Issels, R., Oosterom, A. T., Glabbeke, M., Blay, J. Y. (2007) Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: Analyis of EORTC-ISG-AGITG study 62005. EUROPEAN JOURNAL OF CANCER, 43 (6). pp. 974-978. ISSN 0959-8049

Sharp, S. Y., Boxall, K., Rowlands, M., Prodromou, C., Roe, S. M., Maloney, A., Powers, M., Clarke, P. A., Box, G., Sanderson, S., Patterson, L., Matthews, T. P., Cheung, K. M. J., Ball, K., Hayes, A., Raynaud, F., Marais, R., Pearl, L., Eccles, S., Aherne, W., McDonald, E., Workman, P. (2007) In vitro biological characterization of a novel, synthetic diaryl pyrazole resorcinol class of heat shock protein 90 inhibitors. CANCER RESEARCH, 67 (5). pp. 2206-2216. ISSN 0008-5472

Sharp, S. Y., Prodromou, C., Boxall, K., Powers, M. V., Holmes, J. L., Box, G., Matthews, T. P., Cheung, K. M. J., Kalusa, A., Janmes, K., Hayes, A., Hardcastle, A., Dymock, B., Brough, P. A., Barril, X., Cansfield, J. E., Wright, L., Surgenor, A., Foloppe, N., Hubbard, R. E., Aherne, W., Pearl, L., Jones, K., McDonald, E., Raynaud, F., Eccles, S., Drysdale, M., Workman, P. (2007) Inhibition of the heat shock protein 90 molecular chaperone in vitro and in vivo by novel, synthetic, potent resorcinylic pyrazole/isoxazole amide analogues. MOLECULAR CANCER THERAPEUTICS, 6 (4). pp. 1198-1211. ISSN 1535-7163

Chan, F., Sun, C., Perumal, M., Nguyen, Q. D., Bavetsias, V., McDonald, E., Martins, V., Wilsher, N. E., Raynaud, F. I., Valenti, M., Eccles, S., te Poele, R. T., Workman, P., Aboagye, E. O., Linardopoulos, S. (2007) Mechanism of action of the Aurora kinase inhibitor CCT129202 and in vivo quantification of biological activity. MOLECULAR CANCER THERAPEUTICS, 6 (12 Part 1). pp. 3147-3157. ISSN 1535-7163

Legge, F., Eaton, D., Molife, R., Ferrandina, G., Judson, I., de Bono, J., Kaye, S. (2007) Participation of patients with gynecological cancer in phase I clinical trials: Two years experience in a major cancer center. GYNECOLOGIC ONCOLOGY, 104 (3). pp. 551-556. ISSN 0090-8258

Raynaud, F., Eccles, S., Clarke, P. A., Hayes, A., Nutley, B., Alix, S., Henley, A., Di-Stefano, F., Ahmad, Z., Guillard, S., Bjerke, L. M., Kelland, L., Valenti, M., Patterson, L., Gowan, S., de Haven Brandon, A., Hayakawa, M., Kaizawa, H., Koizumi, T., Ohishi, T., Patel, S., Saghir, N., Parker, P., Waterfield, M., Workman, P. (2007) Pharmacologic Characterization of a Potent Inhibitor of Class I Phosphatidylinositide 3-Kinases. CANCER RESEARCH, 67 (12). pp. 5840-5850. ISSN 0008-5472

Plummer, R., Attard, G., Pacey, S., Li, L., Razak, A., Perrett, R., Barrett, M., Judson, I., Kaye, S., Fox, N. L., Halpern, W., Corey, A., Calvert, H., De Bono, J. (2007) Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers. CLINICAL CANCER RESEARCH, 13 (20). pp. 6187-6194. ISSN 1078-0432

Appleton, K., Mackay, H. J., Judson, I., Plumb, J. A., McCormick, C., Strathdee, G., Lee, C., Barrett, S., Reade, S., Jadayel, D., Tang, A., Bellenger, K., Mackay, L., Setanoians, A., Schatzlein, A., Twelves, C., Kaye, S. B., Brown, R. (2007) Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors. JOURNAL OF CLINICAL ONCOLOGY, 25 (29). pp. 4603-4609. ISSN 0732-183X

Benson, C., White, J., De Bono, J., O'Donnell, A., Raynaud, F., Cruickshank, C., McGrath, H., Walton, M., Workman, P., Kaye, S., Cassidy, J., Gianella-Borradori, A., Judson, I., Twelves, C. (2007) A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days. BRITISH JOURNAL OF CANCER, 96 (1). pp. 29-37. ISSN 0007-0920

Wilsher, N., Court, W. J., Ruddle, R., Newbatt, Y. M., Aherne, W., Sheldrake, P. W., Jones, N. P., Katan, M., Eccles, S. A., Raynaud, F. I. (2007) The phosphoinositide-specific phospholipase C inhibitor U73122 (1-(6-((17 beta-3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione) spontaneously forms conjugates with common components of cell culture medium. DRUG METABOLISM AND DISPOSITION, 35 (7). pp. 1017-1022. ISSN 0090-9556

Wong, O. G. W., Nitkunan, T., Oinuma, I., Zhou, C., Blanc, V., Brown, R. S. D., Bott, S. R. J., Nariculam, J., Box, G., Munson, P., Constantinou, J., Feneley, M. R., Klocker, H., Eccles, S. A., Negishi, M., Freeman, A., Masters, J. R., Williamson, M. (2007) Plexin-B1 mutations in prostate cancer. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 104 (48). pp. 19040-19045. ISSN 0027-8424

Donald, A., McHardy, T., Rowlands, M. G., Hunter, L. J. K., Davies, T. G., Berdini, V., Boyle, R. G., Aherne, G. W., Garrett, M. D., Collins, I. (2007) Rapid evolution of 6-phenylpurine inhibitors of protein kinase B through structure-based design. JOURNAL OF MEDICINAL CHEMISTRY, 50 (10). pp. 2289-2292. ISSN 0022-2623

Williamson, D., Selfe, J., Gordon, T., Lu, Y. J., Pritchard-Jones, K., Murai, K., Jones, P., Workman, P., Shipley, J. (2007) Role for amplification and expression of Glypican-5 in rhabdomyosarcoma. CANCER RESEARCH, 67 (1). pp. 57-65. ISSN 0008-5472

Olsson, A. Y., Feber, A., Edwards, S., Poele, R. T., Giddings, I., Merson, S., Cooper, C. S. (2007) Role of E2F3 expression in modulating cellular proliferation rate in human bladder and prostate cancer cells. ONCOGENE, 26 (7). pp. 1028-1037. ISSN 0950-9232

Sutton, K. M., Hayat, S., Chau, N. M., Cook, S., Pouyssegur, J., Ahmed, A., Perusinghe, N., Le Floch, R., Yang, J., Ashcroft, M. (2007) Selective inhibition of MEK1/2 reveals a differential requirement for ERK1/2 signalling in the regulation of HIF-1 in response to hypoxia and IGF-1. ONCOGENE, 26 (27). pp. 3920-3929. ISSN 0950-9232

Karavasilis, V., Seddon, B. M., Ashley, S., Al-Muderis, O., Fisher, C., Judson, I. (2007) Significant clinical benefit of first-line palliative chemotherapy in advanced soft-tissue sarcoma - Retrospective analysis and identification of prognostic factors in 488 patients. CANCER, 112 (7). pp. 1585-1591. ISSN 0008-543X

Davies, T. G., Verdonk, M. L., Graham, B., Saalau-Bethell, S., Hamlett, C. C., McHardy, T., Collins, I., Garrett, M. D., Workman, P., Woodhead, S. J., Jhoti, H., Barford, D. (2007) A Structural Comparison of Inhibitor Binding to PKB, PKA and PKA-PKB Chimera. JOURNAL OF MOLECULAR BIOLOGY, 367 (3). pp. 882-894. ISSN 0022-2836

Schepelmann, S., Ogilvie, L. M., Hedley, D., Friedlos, F., Martin, J., Scanlon, I., Chen, P., Marais, R., Springer, C. J. (2007) Suicide gene therapy of human colon carcinoma xenografts using an armed oncolytic adenovirus expressing carboxypeptidase G2. CANCER RESEARCH, 67 (10). pp. 4949-4955. ISSN 0008-5472

Luangdilok, S., Box, C., Patterson, L., Court, W., Harrington, K., Pitkin, L., Rhys-Evans, P., O-charoenrat, P., Eccles, S. (2007) Syk tyrosine kinase is linked to cell motility and progression in squamous cell carcinomas of the head and neck. CANCER RESEARCH, 67 (16). pp. 7907-7916. ISSN 0008-5472

Hayakawa, M., Kaizawa, H., Kawaguchi, K., Ishikawa, N., Koizumi, T., Ohishi, T., Yamano, M., Okada, M., Ohta, M., Tsukamoto, S., Raynaud, F. I., Waterfield, M. D., Parker, P., Workman, P. (2007) Synthesis and biological evaluation of imidazo[1,2-a]pyridine derivatives as novel PI3 kinase p110 alpha inhibitors. BIOORGANIC & MEDICINAL CHEMISTRY, 15 (1). pp. 403-412. ISSN 0968-0896

Hayakawa, M., Kaizawa, H., Moritomo, H., Koizumi, T., Ohishi, T., Yamano, M., Okada, M., Ohta, M., Tsukamoto, S., Raynaud, F. I., Workman, P., Waterfield, M. D., Parker, P. (2007) Synthesis and biological evaluation of pyrido[3 ',2': 4,5]furo [3,2-d]pyrimidine derivatives as novel PI3 kinase p110 alpha inhibitors. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 17 (9). pp. 2438-2442. ISSN 0960-894X

Hayakawa, M., Kawaguchi, K. I., Kaizawa, H., Tomonobu, Kaaa, Ohishi, T., Yamano, M., Okada, M., Ohta, M., Tsukamoto, S., Raynaud, F. I., Parker, P., Workman, P., Waterfield, M. D. (2007) Synthesis and biological evaluation of sulfonylhydrazone-substituted imidazo[1,2-a]pyridines as novel PI3 kinase p110 alpha inhibitors. BIOORGANIC & MEDICINAL CHEMISTRY, 15 (17). pp. 5837-5844. ISSN 0968-0896

Caldwell, J. J., Cheung, K. M., Collins, I. (2007) Synthesis of 4-(cyclic dialkylamino)-7-azaindoles by microwave heating of 4-halo-7-azaindoles and cyclic secondary amines. TETRAHEDRON LETTERS, 48 (9). pp. 1527-1529. ISSN 0040-4039

Barril, X., Beswick, M. C., Collier, A., Drysdale, M. J., Dymock, B. W., Fink, A., Grant, K., Howes, R., Jordan, A. M., Massey, A., Surgenor, A., Wayne, J., Workman, P., Wright, L. (2006) 4-Amino derivatives of the Hsp90 inhibitor CCT018159. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 16 (9). pp. 2543-2548. ISSN 0960-894X

Mantoni, T. S., Reid, G., Garrett, M. D. (2006) Androgen receptor activity is inhibited in response to genotoxic agents in a p53-independent manner. ONCOGENE, 25 (22). pp. 3139-3149. ISSN 0950-9232

Sanderson, S., Valenti, M., Gowan, S., Patterson, L., Ahmad, Z., Workman, P., Eccles, S. A. (2006) Benzoquinone ansamycin heat shock protein 90 inhibitors modulate multiple functions required for tumor angiogenesis. MOLECULAR CANCER THERAPEUTICS, 5 (3). pp. 522-532. ISSN 1535-7163

Moreno-Farre, J., Asad, Y., Pacey, S., Workman, P., Raynaud, F. I. (2006) Development and validation of a liquid chromatography/tandem mass spectrometry method for the determination of the novel anticancer agent 17-DMAG in human plasma. RAPID COMMUNICATIONS IN MASS SPECTROMETRY, 20 (19). pp. 2845-2850. ISSN 0951-4198

Atrash, B., Cooper, T. S., Sheldrake, P., Workman, P., McDonald, E. (2006) Development of synthetic routes to macrocyclic compounds based on the HSP90 inhibitor radicicol. TETRAHEDRON LETTERS, 47 (13). pp. 2237-2240. ISSN 0040-4039

Demetri, G. D., van Oosterom, A. T., Garrett, C. R., Blackstein, M. E., Shah, M. H., Verweij, J., McArthur, G., Judson, I. R., Heinrich, M. C., Morgan, J A., Desai, J.D Fletcher, C., George, S., Bello, C. L., Huang, X., Baum, C. M., Casali, P. G. (2006) Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. LANCET, 368 (9544). pp. 1329-1338. ISSN 0140-6736

Sheldrake, P. W., Matteucci, M., McDonald, E. (2006) Facile generation of a library of 5-aryl-2-arylsulfonyl-1,3-thiazoles. SYNLETT, 3 . pp. 460-462. ISSN 0936-5214

Dijkstra, H. P., Gaulon, C., Niculescu-Duvaz, D., Springer, C. J. (2006) A facile synthesis of an oxazolo[5,4]pyrimidin-2-one and a pyrimido[5,4][1,3]oxazin-2-one. SYNLETT, 1 (10). pp. 1519-1522. ISSN 0936-5214

Howes, R., Barril, X., Dymock, B. W, Grant, K., Northfield, C. J., Robertson, A. G. S., Surgenor, A., Wayne, J., Wright, L., James, K., Matthews, T., Cheung, K. M., McDonald, E., Workman, P., Drysdale, M. J. (2006) A fluorescence polarization assay for inhibitors of Hsp90. ANALYTICAL BIOCHEMISTRY, 350 (2). pp. 202-213. ISSN 0003-2697

Downey, M., Houlsworth, R., Maringele, L., Rollie, A., Brehme, M., Galicia, S., Guillard, S., Partington, M., Zubko, M. K., Krogan, N. J., Emili, A., Greenblatt, J. F., Harrington, L., Lydall, D., Durocher, D. (2006) A genome-wide screen identifies the evolutionarily conserved KEOPS complex as a telomere regulator. CELL, 124 (6). pp. 1155-1168. ISSN 0092-8674

Scurr, M., Judson, I. (2006) How to treat the Ewing's family of sarcomas in adult patients. ONCOLOGIST, 11 (1). pp. 65-72. ISSN 1083-7159

Anderson, C. J., Hoare, S. F., Ashcroft, M., Bilsland, A. E., Keith, W. N. (2006) Hypoxic regulation of telomerase gene expression by transcriptional and post-transcriptional mechanisms. ONCOGENE, 25 (1). pp. 61-69. ISSN 0950-9232

Newbatt, Y., Burns, S., Hayward, R., Whittaker, S., Kirk, R., Marshall, C., Springer, C., McDonald, E., Marais, R., Workman, P., Aherne, W., Canc Genome Project, [Group Author] (2006) Identification of inhibitors of the kinase activity of oncogenic (V600E)BRAF in an enzyme cascade high-throughput screen. JOURNAL OF BIOMOLECULAR SCREENING, 11 (2). pp. 145-154. ISSN 1087-0571

Beloueche-Babari, M., Jackson, L. E., Al-Saffar, N. M. S., Eccles, S. A., Raynaud, F. I., Workman, P., Leach, M. O., Ronen, S. M. (2006) Identification of magnetic resonance detectable metabolic changes associated with inhibition of phosphoinositide 3-kinase signaling in human breast cancer cells. MOLECULAR CANCER THERAPEUTICS, 5 (1). pp. 187-196. ISSN 1535-7163

Honma, M., Stubbs, M., Collins, I., Workman, P., Aherne, W., Watt, F. M. (2006) Identification of novel keratinocyte differentiation modulating compounds by high-throughput screening. JOURNAL OF BIOMOLECULAR SCREENING, 11 (8). pp. 977-984. ISSN 1087-0571

Burns, S., Travers, J., Collins, I., Rowlands, M. G., Newbatt, Y., Thompson, N., Garrett, M. D., Workman, P., Aherne, W. (2006) Identification of small-molecule inhibitors of protein kinase B (PKB/AKT) in an AlphaScreen (TM) high-throughput screen. JOURNAL OF BIOMOLECULAR SCREENING, 11 (7). pp. 822-827. ISSN 1087-0571

Dumaz, N., Hayward, R., Martin, J., Ogilvie, L., Hedley, D., Curtin, J. A., Bastian, B. C., Springer, C., Marais, R. (2006) In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signaling. CANCER RESEARCH, 66 (19). pp. 9483-9491. ISSN 0008-5472

Leyton, J., Alao, J. P., Da Costa, M., Stavropoulou, A. V., Latigo, J. R., Perumal, M., Pillai, R., He, Q. M., Atadja, P., Lam, E. W. F., Workman, P., Vigushin, D. M., Aboagye, E. O. (2006) In vivo biological activity of the histone deacetylase inhibitor LA0824 is detectable with 3 '-deoxy-3 '-[F-18]fluorothymidine positron emission tomography. CANCER RESEARCH, 66 (15). pp. 7621-7629. ISSN 0008-5472

Proisy, N., Sharp, S. Y., Boxall, K., Connelly, S., Roe, S. M., Prodromou, C., Slawin, A. M. Z., Pearl, L. H., Workman, P., Moody, C. J. (2006) Inhibition of Hsp90 with synthesis macrolactones: Synthesis and structural and biological evaluation of ring and conformational analogs of radicicol. CHEMISTRY & BIOLOGY, 13 (11). pp. 1203-1215. ISSN 1074-5521

Debiec-Rychter, M., Sciot, R., Le Cesne, A., Schlemmer, M., Hohenberger, P., van Oosterom, A. T., Blay, J. Y., Leyvraz, S., Stul, M., Casali, P. G., Zalcberg, J., Verweij, J., Van Glabbeke, M., Hagemeijer, A., Judson, I., EORTC Soft Tissue Bone Sarcoma Grp, [Group Author], Italian Sarcoma Grp, [Group Author], Australasian GastroIntestinal, [Group Author] (2006) KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. EUROPEAN JOURNAL OF CANCER, 42 (8). pp. 1093-1103. ISSN 0959-8049

Shanley, S., McReynolds, K., Ardern-Jones, A., Ahern, R., Fernando, I., Yarnold, J., Evans, G., Eccles, D., Hodgson, S., Ashley, S., Ashcroft, L., Tutt, A., Bancroft, E., Short, S., Gui, G., Barr, L., Baildam, A., Howell, A., Royle, G., Pierce, L., Easton, D., Eeles, R. (2006) Late toxicity is not increased in BRCA1/BRCA2 mutation carriers undergoing breast radiotherapy in the United Kingdom. CLINICAL CANCER RESEARCH, 12 (23). pp. 7025-7032. ISSN 1078-0432

Foster, S. S., Zubko, M. K., Guillard, S., Lydall, D. (2006) MRX protects telomeric DNA at uncapped telomeres of budding yeast cdc13-1 mutants. DNA REPAIR, 5 (7). pp. 840-851. ISSN 1568-7864

Briassouli, P., Chan, F., Linardopoulos, S. (2006) The N-terminal domain of the Aurora-A Phe-31 variant encodes an E3 ubiquitin ligase and mediates ubiquitination of I kappa B alpha. HUMAN MOLECULAR GENETICS, 15 (22). pp. 3343-3350. ISSN 0964-6906

Knowles, H. J., Poole, R. T., Workman, P., Harris, A. L. (2006) Niacin induces PPAR gamma expression and transcriptional activation in macrophages via HM74 and HM74a-mediated induction of prostaglandin synthesis pathways. BIOCHEMICAL PHARMACOLOGY, 71 (5). pp. 646-656. ISSN 0006-2952

Barker, K. T., Spendlove, H. E., Banu, N. S., Bridge, J. A., Fisher, C., Shipley, J., Garrett, M., Manyonda, I., Houlston, R. S. (2006) No evidence for epigenetic inactivation of furnarate hydratase in leiomyomas and leiomyosarcomas. CANCER LETTERS, 235 (1). pp. 136-140. ISSN 0304-3835

Al-Saffar, N. M. S., Troy, H., de Molina, A. R., Jackson, L. E., Madhu, B., Griffiths, J. R., Leach, M. O., Workman, P., Lacal, J. C., Judson, I. R., Chung, Y. L. (2006) Noninvasive magnetic resonance spectroscopic pharmacodynamic markers of the choline kinase inhibitor MN58b in human carcinoma models. CANCER RESEARCH, 66 (1). pp. 427-434. ISSN 0008-5472

Niculescu-Duvaz, I., Roman, E., Whittaker, S. R., Friedlos, F., Kirk, R., Scanlon, I. J., Davies, L. C., Niculescu-Duvaz, D., Marais, R., Springer, C. J. (2006) Novel inhibitors of B-RAF based on a disubstituted pyrazine scaffold. Generation of a nanomolar lead. JOURNAL OF MEDICINAL CHEMISTRY, 49 (1). pp. 407-416. ISSN 0022-2623

Torr, J. E., Large, J. M., Horton, P. N., Hursthouse, M. B., McDonald, E. (2006) On the nucleophilic tele-substitution of dichloropyrazines by metallated dithianes. TETRAHEDRON LETTERS, 47 (1). pp. 31-34. ISSN 0040-4039

Nielsen, O. S., Reichardt, P., Christensen, T. B., Pink, D., Daugaard, S., Hermans, C., Marreaud, S., van Glabbeke, M., Blay, J., Judson, I. (2006) Phase 1 European Organisation for Research and Treatment of Cancer study determining safety of pegylated liposomal doxorubicin (Caelyx (R)) in combination with ifosfamide in previously untreated adult patients with advanced or metastatic soft tissue sarcomas. EUROPEAN JOURNAL OF CANCER, 42 (14). pp. 2303-2309. ISSN 0959-8049

Lee, C. P., de Jonge, M. J. A., O'Donnell, A. E., Schothorst, K. L., Hanwell, J., Chick, J. B., Brooimans, R. A., Adams, L. M., Drolet, D. W., de Bono, J. S., Kaye, S. B., Judson, I. R., Verweij, J. (2006) A phase I study of a new nucleoside analogue, OSI-7836, using two administration schedules in patients with advanced solid malignancies. CLINICAL CANCER RESEARCH, 12 (9). pp. 2841-2848. ISSN 1078-0432

Mayer, A., Francis, R. J., Sharma, S. K., Tolner, B., Springer, C. J., Martin, J., Boxer, G. M., Bell, J., Green, A. J., Hartley, J. A., Cruickshank, C., Wren, J., Chester, K. A., Begent, R. H. J. (2006) A phase I study of single administration of antibody-directed enzyme prodrug therapy with the recombinant anti-carcinoembryonic antigen antibody-enzyme fusion protein MFECP1 and a bis-iodo phenol mustard prodrug. CLINICAL CANCER RESEARCH, 12 (21). pp. 6509-6516. ISSN 1078-0432

Johnson, P., Geldart, T., Fumoleau, P., Pinel, M. C., Nguyen, L., Judson, I. (2006) Phase I study of vinflunine administered as a 10-minute infusion on days 1 and 8 every 3 weeks. INVESTIGATIONAL NEW DRUGS, 24 (3). pp. 223-231. ISSN 0167-6997

Sain, N., Krishnan, B., Ormerod, M. G., De Rienzo, A., Liu, W. M., Kaye, S. B., Workman, P., Jackman, A. L. (2006) Potentiation of paclitaxel activity by the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin in human ovarian carcinoma cell lines with high levels of activated AKT. MOLECULAR CANCER THERAPEUTICS, 5 (5). pp. 1197-1208. ISSN 1535-7163

Smith, N. F., Hayes, A., James, K., Nutley, B. P., McDonald, E., Henley, A., Dymock, B., Drysdale, M. J., Raynaud, F. I., Workman, P. (2006) Preclinical pharmacokinetics and metabolism of a novel diaryl pyrazole resorcinol series of heat shock protein 90 inhibitors. MOLECULAR CANCER THERAPEUTICS, 5 (6). pp. 1628-1637. ISSN 1535-7163

Van Glabbeke, M., Verweij, J., Casali, P. G., Simes, J., Le Cesne, A., Reichardt, P., Issels, R., Judson, I. R., van Oosterom, A. T., Blay, J. Y. (2006) Predicting toxicities for patients with advanced gastrointestinal stromal tumours treated with imatinib: A study of the European Organisation for Research and Treatment of Cancer, the Italian Sarcoma Group, and the Australasian Gastro-Intestinal Trials Group (EORTC-ISG-AGITG). EUROPEAN JOURNAL OF CANCER, 42 (14). pp. 2277-2285. ISSN 0959-8049

Popat, S., Chen, Z., Zhao, D., Pan, H., Hearle, N., Chandler, I., Shao, Y., Aherne, W., Houlston, R. S. (2006) A prospective, blinded analysis of thymidylate synthase and p53 expression as prognostic markers in the adjuvant treatment of colorectal cancer. ANNALS OF ONCOLOGY, 17 (12). pp. 1810-1817. ISSN 0923-7534

Caldwell, J. J., Collins, I. (2006) Rapid synthesis of 4-benzyl-4-aminopiperidines by addition of Grignard reagents to N-(1-Boc-piperidin-4-ylidene)-tert-butanesulfinyl imine. SYNLETT (16). pp. 2565-2568. ISSN 0936-5214

Sodha, N., Mantoni, T. S., Tavtigian, S. V., Eeles, R., Garrett, M. D. (2006) Rare germ line CHEK2 variants identified in breast cancer families encode proteins that show impaired activation. CANCER RESEARCH, 66 (18). pp. 8966-8970. ISSN 0008-5472

Carroll, V. A., Ashcroft, M. (2006) Role of hypoxia-inducible factor (HIF)-1 alpha-versus HIF-2 alpha in the regulation of HIF target genes in response to hypoxia, insulin-like growth factor-1, or loss of von Hippel-Lindau function: Implications for targeting the HIF pathway. CANCER RESEARCH, 66 (12). pp. 6264-6270. ISSN 0008-5472

Spicer, J., Banerji, U., Hanwell, J., Judson, I. (2006) Stable disease for four years in metastatic malignant melanoma treated with the heat shock protein inhibitor 17-AAG. TARGETED ONCOLOGY, 1 (1). pp. 54-55. ISSN 1776-2596

Collins, I., Caldwell, J., Fonseca, T., Donald, A., Bavetsias, V., Hunter, L. J. K., Garrett, M. D., Rowlands, M. G., Aherne, G. W., Davies, T. G., Berdini, V., Woodhead, S. J., Davis, D., Seavers, L. C. A., Wyatt, P. G., Workman, P., McDonald, E. (2006) Structure-based design of isoquinoline-5-sulfonamide inhibitors of protein kinase B. BIOORGANIC & MEDICINAL CHEMISTRY, 14 (4). pp. 1255-1273. ISSN 0968-0896

Nicoll, K., Robertson, J., Lant, N., Kelland, L. R., Rogers, P. M., Robins, D. J. (2006) Synthesis and antimelanoma activity of reversed amide analogues of N-acetyl-4-S-cysteaminylphenol. ONCOLOGY RESEARCH, 16 (2). pp. 97-106. ISSN 0965-0407

Hayakawa, M., Kaizawa, H., Moritomo, H., Koizumi, T., Ohishi, T., Okada, M., Ohta, M., Tsukamoto, S., Parker, P., Workman, P., Waterfield, M. (2006) Synthesis and biological evaluation of 4-morpholino-2-phenylquinazolines and related derivatives as novel PI3 kinase p110 alpha inhibitors. BIOORGANIC & MEDICINAL CHEMISTRY, 14 (20). pp. 6847-6858. ISSN 0968-0896

Cooper, T. S., Atrash, B., Sheldrake, P., Workman, P., McDonald, E. (2006) Synthesis of resorcinylic macrocycles related to radicicol via ring-closing metathesis. TETRAHEDRON LETTERS, 47 (13). pp. 2241-2243. ISSN 0040-4039

Large, J. M., Clarke, M., Williamson, D. M., McDonald, E., Collins, I. (2006) Synthesis of trisubstituted pyrimidines by regioselective SNAr and Suzuki reactions of polyhalopyrimidines. SYNLETT (6). pp. 861-864. ISSN 0936-5214

Powers, M. V., Workman, P. (2006) Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors. ENDOCRINE-RELATED CANCER, 13 (Supplement 1). S125-S135. ISSN 1351-0088

Lord, C. J., Garrett, M. D., Ashworth, A. (2006) Targeting the double-strand DNA break repair pathway as a therapeutic strategy. CLINICAL CANCER RESEARCH, 12 (15). pp. 4463-4468. ISSN 1078-0432

Oliver, A. W., Paul, A., Boxall, K. J., Barrie, S. E., Aherne, G. W., Garrett, M. D., Mittnacht, S., Pearl, L. H. (2006) Trans-activation of the DNA-damage signalling protein kinase Chk2 by T-loop exchange. EMBO JOURNAL, 25 (13). pp. 3179-3190. ISSN 0261-4189

Martins, V., Asad, Y., Wilsher, N., Raynaud, F. (2006) A validated liquid chromatographic-tandem mass spectroscopy method for the quantification of abiraterone acetate and abiraterone in human plasma. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 843 (2). pp. 262-267. ISSN 1570-0232

Naumova, E., Ubezio, P., Garofalo, A., Borsotti, P., Cassis, L., Riccardi, E., Scanziani, E., Eccles, S. A., Bani, M. R., Giavazzi, R. (2006) The vascular targeting property of paclitaxel is enhanced by SU6668, a receptor tyrosine kinase inhibitor, causing apoptosis of endothelial cells and inhibition of angiogenesis. CLINICAL CANCER RESEARCH, 12 (6). pp. 1839-1849. ISSN 1078-0432

Brough, P. A., Barril, X., Beswick, M., Dymock, B. W., Drysdale, M. J., Wright, L., Grant, K., Massey, A., Surgenor, A., Workman, P. (2005) 3-(5-chloro-2,4-dihydroxyphenyl)-pyrazole-4-carboxamides as inhibitors of the Hsp90 molecular chaperone. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 15 (23). pp. 5197-5201. ISSN 0960-894X

da Rocha Dias, S., Friedlos, F., Light, Y., Springer, C., Workman, P., Marais, R. (2005) Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin. CANCER RESEARCH, 65 (23). pp. 10686-10691. ISSN 0008-5472

Leach, M. O., Brindle, K. M., Evelhoch, J. L., Griffiths, J. R., Horsman, M. R., Jackson, A., Jayson, G. C., Judson, I. R., Knopp, M. V., Maxwell, R. J., McIntyre, D., Padhani, A. R., Price, P., Rathbone, R., Rustin, G. J., Tofts, P. S., Tozer, G. M., Vennart, W., Waterton, J. C., Williams, S. R., Workman, P. (2005) The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations. BRITISH JOURNAL OF CANCER, 92 (9). pp. 1599-1610. ISSN 0007-0920

Gibbs, D. D., Theti, D. S., Wood, N., Green, M., Raynaud, F., Valenti, M., Forster, M. D., Mitchell, F., Bavetsias, V., Henderson, E., Jackman, A. L. (2005) BGC 945, a novel tumor-selective thymidylate synthase inhibitor targeted to alpha-folate receptor-overexpressing tumors. CANCER RESEARCH, 65 (24). pp. 11721-11728. ISSN 0008-5472

Reynisson J, Steenken S (2005) The calculated base pairing energy of 8-oxoguanine in the syn- anti conformation with cytosine, thymine, adenine and guanine. JOURNAL OF MOLECULAR STRUCTURE-THEOCHEM, 723 (1-3). pp. 29-36. ISSN 0166-1280

Powles, T., te Poele, R., Shamash, J., Chaplin, T., Propper, D., Joel, S., Oliver, T., Liu, W. M. (2005) Cannabis-induced cytotoxicity in leukemic cell lines: the role of the cannabinoid receptors and the MAPK pathway. BLOOD, 105 (3). pp. 1214-1221. ISSN 0006-4971

Jones, R. L., Fisher, C., Al-Muderis, O., Judson, I. R. (2005) Differential sensitivity of liposarcoma subtypes to chemotherapy. EUROPEAN JOURNAL OF CANCER, 41 (18). pp. 2853-2860. ISSN 0959-8049

McDonald, E., Bavetsias, V. (2005) Discovery of small molecules as anticancer agents: the role of the medicinal chemist in the discovery of new cancer therapeutics. FORUM OF CLINICAL ONCOLOGY, 4 . pp. 51-57.

Ma ESF, Bates WD, Edmunds A, Kelland LR, Fojo T, Farrell N (2005) Enhancement of aqueous solubility and stability employing a trans acetate axis in trans planar amine platinum compounds while maintaining the biological profile. JOURNAL OF MEDICINAL CHEMISTRY, 48 (18). pp. 5651-5654. ISSN 0022-2623

Walton, M. I., Wilson, S. C., Hardcastle, I. R., Mirza, A. R., Workman, P. (2005) An evaluation of the ability of pifithrin-alpha and to inhibit -beta function in two wild-type p53 human tumor cell lines. MOLECULAR CANCER THERAPEUTICS, 4 (9). pp. 1369-1377. ISSN 1535-7163

Edwards, S., Campbell, C., Flohr, P., Shipley, J., Giddings, I., te-Poele, R., Dodson, A., Foster, C., Clark, J., Jhavar, S., Kovacs, G., Cooper, C. S. (2005) Expression analysis onto microarrays of randomly selected cDNA clones highlights HOXB13 as a marker of human prostate cancer. BRITISH JOURNAL OF CANCER, 92 (2). pp. 376-381. ISSN 0007-0920

Gaulon, C., Dijkstra, H. P., Springer, C. J. (2005) A general and facile route to new trisubstituted purin-8-ones. SYNTHESIS-STUTTGART, 13 . pp. 2227-2233. ISSN 0039-7881

Niculescu-Duvaz, D., Scanlon, I., Niculescu-Duvaz, I., Springer, C. J. (2005) A higher yielding synthesis of the clinical prodrug ZD2767P using di-protected 4-[N,N-bis(2-hydroxyethyl)amino]phenyl chloroformate. TETRAHEDRON LETTERS, 46 (40). pp. 6919-6922. ISSN 0040-4039

Payne GS, Dzik-Jurasz ASK, Mancini L, Nutley B, Raynaud F, Leach MO (2005) Identification of biliary metabolites of ifosfamide using P-31 magnetic resonance spectroscopy and mass spectrometry. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 56 (4). pp. 409-414. ISSN 0344-5704

Chau, N. M., Rogers, P., Aherne, W., Carroll, V., Collins, I., McDonald, E., Workman, P., Ashcroft, M. (2005) Identification of novel small molecule inhibitors of hypoxia-inducible factor-1 that differentially block hypoxia-inducible factor-1 activity and hypoxia-inducible factor-1 alpha induction in response to hypoxic stress and growth factors. CANCER RESEARCH, 65 (11). pp. 4918-4928. ISSN 0008-5472

Cheung KMJ, Matthews TP, James K, Rowlands MG, Boxall KJ, Sharp SY, Maloney A, Roe SM, Prodromou C, Pearl LH, Aherne GW, McDonald E, Workman P (2005) The identification, synthesis, protein crystal structure and in vitro biochemical evaluation of a new 3,4-diarylpyrazole class of Hsp90 inhibitors. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 15 (14). pp. 3338-3343. ISSN 0960-894X

Judson I, Ma PM, Peng B, Verweij J, Racine A, di Paola FD, van Glabbeke M, Dimitrijevic S, Scurr M, Dumez H, van Oosterom A (2005) Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: a retrospective population pharmacokinetic study over time. EORTC Soft Tissue and Bone Sarcoma Group. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 55 (4). pp. 379-386. ISSN 0344-5704

Raynaud, F. I., Whittaker, S. R., Fischer, P. M., McClue, S., Walton, M. I., Barrie, S. E., Garrett, M. D., Rogers, P., Clarke, S. J., Kelland, L. R., Valenti, M., Brunton, L., Eccles, S., Lane, D. P., Workman, P. (2005) In vitro and in vivo pharmacokinetic-pharmacodynamic relationships for the trisubstituted aminopurine cyclin-dependent kinase inhibitors olomoucine, bohemine and CYC202. CLINICAL CANCER RESEARCH, 11 (13). pp. 4875-4887. ISSN 1078-0432

Van Glabbeke M, Verweij J, Casali PG, Le Cesne A, Hohenberger P, Ray-Coquard I, Schlemmer M, van Oosterom AT, Goldstein D, Sciot R, Hogendoorn PCW, Brown M, Bertulli R, Judson IR (2005) Initial and late resistance to imatinib in advanced gastrointestinal stromal. tumors are predicted by different prognostic factors: A European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study. JOURNAL OF CLINICAL ONCOLOGY, 23 (24). pp. 5795-5804. ISSN 0732-183X

McSheehy, P. M. J., Port, R. E., Rodrigues, L. M., Robinson, S. P., Stubbs, M., van der Borns, K., Peters, G. J., Judson, I. R., Leach, M. O., Griffiths, J. R. (2005) Investigations in vivo of the effects of carbogen breathing on 5-fluorouracil pharmacokinetics and physiology of solid rodent tumours. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 55 (2). pp. 117-128. ISSN 0344-5704

Stimson, L., Rowlands, M. G., Newbatt, Y. M., Smith, N. F., Raynaud, F. I., Rogers, P., Bavetsias, V., Gorsuch, S., Jarman, M., Bannister, A., Kouzarides, T., McDonald, E., Workman, P., Aherne, G. W. (2005) Isothiazolones as inhibitors of PCAF and p300 histone acetyltransferase activity. MOLECULAR CANCER THERAPEUTICS, 4 (10). pp. 1521-1532. ISSN 1535-7163

Wood, N., Gibbs, D. D., Jackman, A. L., Henley, A., Workman, P., Raynaud, F. (2005) A liquid chromatographic-tandem mass spectrometric method for the determination of two selective thymidylate synthase inhibitors, BGC945 and BGC638, in mouse plasma. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 824 (1-2). pp. 181-188. ISSN 1570-0232

Beloueche-Babari, M., Jackson, L. E., Al-Saffar, N. M. S., Workman, P., Leach, M. O., Ronen, S. M. (2005) Magnetic resonance spectroscopy monitoring of mitogen-activated protein kinase signaling inhibition. CANCER RESEARCH, 65 (8). pp. 3356-3363. ISSN 0008-5472

Nutley, B. P., Raynaud, F. I., Wilson, S. C., Fischer, P. M., Hayes, A., Goddard, P. M., McClue, S. J., Jarman, M., Lane, D. P., Workman, P. (2005) Metabolism and pharmacokinetics of the cyclin-dependent kinase inhibitor R-roscovitine in the mouse. MOLECULAR CANCER THERAPEUTICS, 4 (1). pp. 125-139. ISSN 1535-7163

Scurr M, Judson I (2005) Neoadjuvant and adjuvant therapy for extremity soft tissue sarcomas. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 19 (3). p. 489. ISSN 0889-8588

Davies, L. C., Friedlos, F., Hedley, D., Martin, J., Ogilvie, L. M., Scanlon, I. J., Springer, C. J. (2005) Novel fluorinated prodrugs for activation by carboxypeptidase G2 showing good in vivo antitumor activity in gene-directed enzyme prodrug therapy. JOURNAL OF MEDICINAL CHEMISTRY, 48 (16). pp. 5321-5328. ISSN 0022-2623

Dymock BW, Barril X, Brough PA, Cansfield JE, Massey A, McDonald E, Hubbard RE, Surgenor A, Roughley SD, Webb P, Workman P, Wright L, Drysdale MJ (2005) Novel, potent small-molecule inhibitors of the molecular chaperone Hsp90 discovered through structure-based design. JOURNAL OF MEDICINAL CHEMISTRY, 48 (13). pp. 4212-4215. ISSN 0022-2623

Reynisson, J., Steenken, S. (2005) One-electron reduction of 2-aminopurine in the aqueous phase. A DFT and pulse radiolysis study. PHYSICAL CHEMISTRY CHEMICAL PHYSICS, 7 (4). pp. 659-665. ISSN 1463-9076

Banerji, U., Walton, M., Raynaud, F., Grimshaw, R., Kelland, L., Valenti, M., Judson, I., Workman, P. (2005) Pharmacokinetic-pharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft models. CLINICAL CANCER RESEARCH, 11 (19). pp. 7023-7032. ISSN 1078-0432

Benepal, T., Jackman, A., Pyle, L., Bate, S., Hardcastle, A., Aherne, W., Mitchell, F., Simmons, L., Ruddle, R., Raynaud, F., Gore, M. (2005) A phase I pharmacokinetic and pharmacodynamic study of BGC9331 and carboplatin in relapsed gynaecological malignancies. BRITISH JOURNAL OF CANCER, 93 (8). pp. 868-875. ISSN 0007-0920

Banerji, U., O'Donnell, A., Scurr, M., Pacey, S., Stapleton, S., Asad, Y., Simmons, L., Maloney, A., Raynaud, F., Campbell, M., Walton, M., Lakhani, S., Kaye, S., Workman, P., Judson, I. (2005) Phase I pharmacokinetic and pharmacodynarnic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. JOURNAL OF CLINICAL ONCOLOGY, 23 (18). pp. 4152-4161. ISSN 0732-183X

O'Donnell, A., Padhani, A., Hayes, C., Kakkar, A. J., Leach, M., Trigo, J. M., Scurr, M., Raynaud, F., Phillips, S., Aherne, W., Hardcastle, A., Workman, P., Hannah, A., Judson, I. (2005) A phase I study of the angiogenesis inhibitor SU5416 (semaxanib) in solid tumours, incorporating dynamic contrast MR pharmacodynamic end points. BRITISH JOURNAL OF CANCER, 93 (8). pp. 876-883. ISSN 0007-0920

Le Cesne A, Blay JY, Judson I, Van Oosterom A, Verweij J, Radford J, Lorigan P, Rodenhuis S, Ray-Coquard I, Bonvalot S, Collin F, Jimeno J, Di Paola E, Van Glabbeke M, Nielsen OS (2005) Phase II study of ET-743 in advanced soft tissue sarcomas: A European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. JOURNAL OF CLINICAL ONCOLOGY, 23 (3). pp. 576-584. ISSN 0732-183X

Guo, Y., Yang, K., Harwalkar, J., Nye, J. M., Mason, D. R., Garrett, M. D., Hitomi, M., Stacey, D. W. (2005) Phosphorylation of cyclin D1 at Thr 286 during S phase leads to its proteasomal degradation and allows efficient DNA synthesis. ONCOGENE, 24 (16). pp. 2599-2612. ISSN 0950-9232

Jones, N. P., Peak, J., Brader, S., Eccles, S. A., Katan, M. (2005) PLC gamma 1 is essential for early events in integrin signalling required for cell motility. JOURNAL OF CELL SCIENCE, 118 (12). pp. 2695-2706. ISSN 0021-9533

Nutley, B. P., Smith, N. F., Hayes, A., Kelland, L. R., Brunton, L., Golding, B. T., Smith, G. C. M., Martin, N. M. B., Workman, P., Raynaud, F. I. (2005) Preclinical pharmacokinetics and metabolism of a novel prototype DNA-PK inhibitor NU7026. BRITISH JOURNAL OF CANCER, 93 (9). pp. 1011-1018. ISSN 0007-0920

Spurrell, E. L., Fisher, C., Thomas, J. M., Judson, I. R. (2005) Prognostic factors in advanced synovial sarcoma: an analysis of 104 patients treated at the Royal Marsden Hospital. ANNALS OF ONCOLOGY, 16 (3). pp. 437-444. ISSN 0923-7534

Perani, M., Antonson, P., Hamoudi, R., Ingram, C. J. E., Cooper, C. S., Garrett, M. D., Goodwin, G. H. (2005) The proto-oncoprotein SYT interacts with SYT-interacting protein/co-activator activator (SIP/CoAA), a human nuclear receptor co-activator with similarity to EWS and TLS/FUS family of proteins. JOURNAL OF BIOLOGICAL CHEMISTRY, 280 (52). pp. 42863-42876. ISSN 0021-9258

Therasse, P., Le Cesne, A., Van Glabbeke, M., Verweij, J., Judson, I. (2005) RECIST vs. WHO: Prospective comparison of response criteria in an EORTC phase II clinical trial investigating ET-743 in advanced soft tissue sarcoma. EUROPEAN JOURNAL OF CANCER, 41 (10). pp. 1426-1430. ISSN 0959-8049

Rocha, S., Garrett, M. D., Campbell, K. J., Schumm, K., Perkins, N. D. (2005) Regulation of NF-kappa B and p53 through activation of ATR and Chk1 by the ARF tumour suppressor. EMBO JOURNAL, 24 (6). pp. 1157-1169. ISSN 0261-4189

Attard, G., Belldegrun, A. S., de Bono, J. S. (2005) Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer. BJU INTERNATIONAL, 96 (9). pp. 1241-1246. ISSN 1464-4096

Hardcastle A, Boxall K, Richards J, Tomlin P, Sharp S, Clarke P, Workman P, Aherne W (2005) Solid-phase immunoassays in mechanism-based drug discovery: Their application in the development of inhibitors of the molecular chaperone heat-shock protein 90. ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES, 3 (3). pp. 273-285. ISSN 1540-658X

Ferguson, J., Rogers, P. M., Kelland, L. R., Robins, D. J. (2005) Synthesis and antimelanoma activity of sterically congested tertiary amide analogues of N-acetyl-4-S-cysteaminylphenol. ONCOLOGY RESEARCH, 15 (2). pp. 87-94. ISSN 0965-0407

Harris, A. L., Yang, X. H., Hegmans, A., Povirk, L., Ryan, J. J., Kelland, L., Farrell, N. P. (2005) Synthesis, characterization, and cytotoxicity of a novel highly charged trinuclear platinum compound. Enhancement of cellular uptake with charge. INORGANIC CHEMISTRY, 44 (26). pp. 9598-9600. ISSN 0020-1669

Osborne MR, Arlt VM, Kliem C, Hull WE, Mirza A, Bieler CA, Schmeiser HH, Phillips DH (2005) Synthesis, characterization, and P-32-postlabeling analysis of DNA adducts derived from the environmental contaminant 3-Nitrobenzanthrone. CHEMICAL RESEARCH IN TOXICOLOGY, 18 (6). pp. 1056-1070. ISSN 0893-228X

Schepelmann, S., Hallenbeck, P., Ogilvie, L. M., Hedley, D., Friedlos, F., Martin, J., Scanlon, I., Hay, C., Hawkins, L. K., Marais, R., Springer, C. J. (2005) Systemic gene-directed enzyme prodrug therapy of hepatocellular carcinoma using a targeted adenovirus armed with carboxypeptidase G2. CANCER RESEARCH, 65 (12). pp. 5003-5008. ISSN 0008-5472

Collins I, Garrett MD (2005) Targeting the cell division cycle in cancer: CDK and cell cycle checkpoint kinase inhibitors. CURRENT OPINION IN PHARMACOLOGY, 5 (4). pp. 366-373. ISSN 1471-4892

Gutierrez CD, Bavetsias V, McDonald E (2005) TiCl((OPr)-Pr-i)(3) and NaBH(OAc)(3): an efficient reagent combination for the reductive amination of aldehydes by electron-deficient amines. TETRAHEDRON LETTERS, 46 (20). pp. 3595-3597. ISSN 0040-4039

Bavetsias, V,, Henderson, E. A., McDonald, E. (2004) 2-pivalamido-3H-pyrimidin-4-one derivatives: convenient pivalamide hydrolysis using Fe(NO3)(3) in MeOH. TETRAHEDRON LETTERS, 45 (29). pp. 5643-5644. ISSN 0040-4039

Workman, P. (2004) Altered states: selectively drugging the Hsp90 cancer chaperone. TRENDS IN MOLECULAR MEDICINE, 10 (2). pp. 47-51. ISSN 1471-4914

Varvaresou A, Iakovou K, Gikas E, Fichtner I, Fiebig HH, Kelland LR, Double JA, Bibby MC, Hendriks HR (2004) Antitumor activity of imidazothioxanthones in murine and human tumor models in vitro and in vivo. ANTICANCER RESEARCH, 24 (2B). pp. 907-919. ISSN 0250-7005

Wellbrock, C., Ogilvie, L., Hedley, D., Karasarides, M., Martin, J., Niculescu-Duvaz, D., Springer, C. J., Marais, R. (2004) B-V599E-RAF is an oncogene in melanocytes. CANCER RESEARCH, 64 (7). pp. 2338-2442. ISSN 0008-5472

Johnston SRD, Gumbrell LA, Evans TRJ, Coleman RE, Smith IE, Twelves CJ, Soukop M, Rea DW, Earl HM, Howell A, Jones A, Canney P, Powles TJ, Haynes BP, Nutley B, Grimshaw R, Jarman M, Halbert GW, Brampton M, Haviland J, Dowsett M, Coombes RC (2004) A Cancer Research (UK) randomized phase II study of idoxifene in patients with locally advanced/metastatic breast cancer resistant to tamoxifen. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 53 (4). pp. 341-348. ISSN 0344-5704

Spurrell, E. L., Yeo, Y. C., Rollason, T. P., Judson, I. R. (2004) A Case of Ovarian Fibromatosis and Massive Ovarian Oedema Associated With Intra-Abdominal Fibromatosis, Sclerosing Peritonitis and Meig's Syndrome. SARCOMA, 8 (4). pp. 113-121. ISSN 1357-714X

Raynaud FI, Fischer PM, Nutley BP, Goddard PM, Lane DP, Workman P (2004) Cassette dosing pharmacokinetics of a library of 2,6,9-trisubstituted purine cyclin-dependent kinase 2 inhibitors prepared by parallel synthesis. MOLECULAR CANCER THERAPEUTICS, 3 (3). pp. 353-362. ISSN 1535-7163

Clarke, P. A., Pestell, K. E., Di Stefano, F., Workman, P., Walton, M. I. (2004) Characterisation of molecular events following cisplatin treatment of two curable ovarian cancer models: contrasting role for p53 induction and apoptosis in vivo. BRITISH JOURNAL OF CANCER, 91 (8). pp. 1614-1623. ISSN 0007-0920

Rogers SJ, Harrington KJ, Eccles SA, Nutting CM (2004) Combination epidermal growth factor receptor inhibition and radical radiotherapy for NSCLC. EXPERT REVIEW OF ANTICANCER THERAPY, 4 (4). pp. 569-583. ISSN 1473-7140

Jackman AL, Kaye S, Workman P (2004) The combination of cytotoxic and molecularly targeted therapies - can it be done? DRUG DISCOVERY TODAY: THERAPEUTIC STRATEGIES, 1 (4). pp. 445-454. ISSN 1740-6773

Workman, P. (2004) Combinatorial attack on multistep oncogenesis by inhibiting the Hsp90 molecular chaperone. CANCER LETTERS, 206 (2). pp. 149-157. ISSN 0304-3835

Whittaker, S. R., Walton, M. I., Garrett, M. D., Workman, P. (2004) The cyclin-dependent kinase inhibitor CYC202 (R-roscovitine) inhibits retinoblastoma protein phosphorylation, causes loss of cyclin D1, and activates the mitogen-activated protein kinase pathway. CANCER RESEARCH, 64 (1). pp. 262-272. ISSN 0008-5472

Renshaw, J., Orr, R. M., Walton, M. I., Poele, R. T., Williams, R. D., Wancewicz, E. V., Monia, B. P., Workman, P., Pritchard-Jones, K. (2004) Disruption of WT1 gene expression and exon 5 splicing following cytotoxic drug treatment: Antisense down-regulation of exon 5 alters target gene expression and inhibits cell survival. MOLECULAR CANCER THERAPEUTICS, 3 (11). pp. 1467-1484. ISSN 1535-7163

Workman P (2004) Drug discovery strategies: Technologies to accelerate translation from target to drug. JOURNAL OF CHEMOTHERAPY, 16 (Supplement 4). pp. 13-15. ISSN 1120-009X

Harrison RJ, Reszka AP, Haider SM, Romagnoli B, Morrell J, Read MA, Gowan SM, Incles CM, Kelland LR, Neidle S (2004) Evaluation of by disubstituted acridone derivatives as telomerase inhibitors: the importance of G-quadruplex binding. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 14 (23). pp. 5845-5849. ISSN 0960-894X

Smith NF, Hayes A, Nutley BP, Raynaud FI, Workman P (2004) Evaluation of the cassette dosing approach for assessing the pharmacokinetics of geldanamycin analogues in mice. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 54 (6). pp. 475-486. ISSN 0344-5704

Zubko, M. K., Guillard, S., Lydall, D. (2004) Exo1 and Rad24 differentially regulate generation of ssDNA at telomeres of Saccharomyces cerevisiae cdc13-1 mutants. GENETICS, 168 (1). pp. 103-115. ISSN 0016-6731

Griffiths, G. J., Koh, M. Y., Brunton, V. G., Cawthorne, C., Reeves, N. A., Greaves, M., Tilby, M. J., Pearson, D. G., Ottley, C. J., Workman, P., Frame, M. C., Dive, C. (2004) Expression of kinase-defective mutants of c-Src in human metastatic colon cancer cells decreases Bcl-x(L) and increases oxaliplatin- and Fas-induced apoptosis. JOURNAL OF BIOLOGICAL CHEMISTRY, 279 (44). pp. 46113-46121. ISSN 0021-9258

Lee, Y. F., John, M., Falconer, A., Edwards, S., Clark, J., Flohr, P., Roe, T., Wang, R. B., Shipley, J., Grimer, R. J., Mangham, D. C., Thomas, J. M., Fisher, C., Judson, I., Cooper, C. S. (2004) A gene expression signature associated with metastatic outcome in human leiomyosarcomas. CANCER RESEARCH, 64 (20). pp. 7201-7204. ISSN 0008-5472

Bardos, J. I., Chau, N. M., Ashcroft, M. (2004) Growth factor-mediated induction of HDM2 positively regulates hypoxia-inducible factor 1 alpha expression. MOLECULAR AND CELLULAR BIOLOGY, 24 (7). pp. 2905-2914. ISSN 0270-7306

Sun CB, Newbatt Y, Douglas L, Workman P, Aherne W, Linardopoulos S (2004) High-throughput screening assay for identification of small molecule inhibitors of Aurora2/STK15 kinase. JOURNAL OF BIOMOLECULAR SCREENING, 9 (5). pp. 391-397. ISSN 1087-0571

Rowlands MG, Newbatt YM, Prodromou C, Pearl LH, Workman P, Aherne W (2004) High-throughput screening assay for inhibitors of heat-shock protein 90 ATPase activity. ANALYTICAL BIOCHEMISTRY, 327 (2). pp. 176-183. ISSN 0003-2697

Kristeleit R, Stimson L, Workman P, Aherne W (2004) Histone modification enzymes: novel targets for cancer drugs. EXPERT OPINION ON EMERGING DRUGS, 9 (1). pp. 135-154. ISSN 1472-8214

O'Donnell, A., Judson, I., Dowsett, M., Raynaud, F., Dearnaley, D., Mason, M., Harland, S., Robbins, A., Halbert, G., Nutley, B., Jarman, M. (2004) Hormonal impact of the 17 alpha-hydroxylase/C-17,C-20-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. BRITISH JOURNAL OF CANCER, 90 (12). pp. 2317-2325. ISSN 0007-0920

Barthel, H., Wilson, H., Collingridge, D. R., Brown, G., Osman, S., Luthra, S. K., Brady, F., Workman, P., Price, P. M., Aboagye, E. O. (2004) In vivo evaluation of [F-18]fluoroetanidazole as a new marker for imaging tumour hypoxia with positron emission tomography. BRITISH JOURNAL OF CANCER, 90 (11). pp. 2232-2242. ISSN 0007-0920

Workman P (2004) Inhibiting the phosphoinositide 3-kinase pathway for cancer treatment. BIOCHEMICAL SOCIETY TRANSACTIONS, 32 (Part 2). pp. 393-396. ISSN 0300-5127

Wan, P. T. C., Garnett, M. J., Roe, S. M., Lee, S., Niculescu-Duvaz, D., Good, V. M., Cancer Genome Project, [Group Author], Jones, C. M., Marshall, C. J., Springer, C. J., Barford, D., Marais, R. (2004) Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. CELL, 116 (6). pp. 855-867. ISSN 0092-8674

Chung, Y. L., Troy, H., Judson, I. R., Leek, R., Leach, M. O., Stubbs, M., Harris, A. L., Griffiths, J. R. (2004) Noninvasive measurements of capecitabine metabolism in bladder tumors overexpressing thymidine phosphorylase by fluorine-19 magnetic resonance spectroscopy. CLINICAL CANCER RESEARCH, 10 (11). pp. 3863-3870. ISSN 1078-0432

de Jonge, M. J. A., Kaye, S., Verweij, J., Brock, C., Reade, S., Scurr, M., van Doorn, L., Verheij, C., Loos, W., Brindley, C., Mistry, P., Cooper, M., Judson, I. (2004) Phase I and pharmacokinetic study of XR11576, an oral topoisomerase I and II inhibitor, administered on days 1-5 of a 3-weekly cycle in patients with advanced solid tumours. BRITISH JOURNAL OF CANCER, 91 (8). pp. 1459-1465. ISSN 0007-0920

Harries, M., O'Donnell, A., Scurr, M., Reade, S., Cole, C., Judson, I., Greystoke, A., Twelves, C., Kaye, S. (2004) Phase I/II study of DHA-paclitaxel in combination with carboplatin in patients with advanced malignant solid tumours. BRITISH JOURNAL OF CANCER, 91 (9). pp. 1651-1655. ISSN 0007-0920

Blay JY, Le Cesne A, Verweij J, Scurr M, Seynaeve C, Bonvalot S, Hogendoorn P, Jimeno J, Evrard V, van Glabbeke M, Judson I (2004) A phase II study of ET-743/trabectedin ('Yondelis') for patients with advanced gastrointestinal stromal tumours. EUROPEAN JOURNAL OF CANCER, 40 (9). pp. 1327-1331. ISSN 0959-8049

Verweij J, Casali PG, Zalcberg J, LeCesne A, Reichardt P, Blay JY, Issels R, van Oosterom A, Hogendoorn PCW, Van Glabbeke M, Bertulli R, Judson I (2004) Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. LANCET, 364 (9440). pp. 1127-1134. ISSN 0140-6736

O-Charoenrat P, Wongkajornsilp A, Rhys-Evans PH, Eccles SA (2004) Signaling pathways required for matrix metalloproteinase-9 induction by betacellulin in head-and-neck squamous carcinoma cells. INTERNATIONAL JOURNAL OF CANCER, 111 (2). pp. 174-183. ISSN 0020-7136

Niculescu-Duvaz, I., Scanlon, I., Niculescu-Duvaz, D., Friedlos, F., Martin, J., Marais, R., Springer, C. J. (2004) Significant differences in biological parameters between prodrugs cleavable by carboxypeptidase G2 that generate 3,5-difluoro-phenol and -aniline nitrogen mustards in gene-directed enzyme prodrug therapy systems. JOURNAL OF MEDICINAL CHEMISTRY, 23 (5). pp. 1153-1165. ISSN 0022-2623

Hartley, J. A., Spanswick, V. J., Brooks, N., Clingen, P. H., McHugh, P. J., Hochhauser, D., Pedley, R. B., Kelland, L. R., Alley, M. C., Schultz, R., Hollingshead, M. G., Schweikart, K. M., Tomaszewski, J. E., Sausville, E. A., Gregson, S. J., Howard, P. W., Thurston, D. E. (2004) SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity. Part 1: Cellular pharmacology, in vitro and initial in vivo antitumor activity. CANCER RESEARCH, 64 (18). pp. 6693-6699. ISSN 0008-5472

Spruce, B. A., Campbell, L. A., McTavish, N., Cooper, M. A., Appleyard, M. V. L., O'Neill, M., Howie, J., Samson, J., Watt, S., Murray, K., McLean, D., Leslie, N. R., Safrany, S. T., Ferguson, M. J., Peters, J. A., Prescott, A. R., Box, G., Hayes, A., Nutley, B., Raynaud, F., Downes, C. P., Lambert, J. J., Thompson, A. M., Eccles, S. (2004) Small molecule antagonists of the sigma-1 receptor cause selective release of the death program in tumor and self- reliant cells and inhibit tumor growth in vitro and in vivo. CANCER RESEARCH, 64 (14). pp. 4875-4886. ISSN 0008-5472

Wright L, Barril X, Dymock B, Sheridan L, Surgenor A, Beswick M, Drysdale M, Collier A, Massey A, Davies N, Fink A, Fromont C, Aherne W, Boxall K, Sharp S, Workman P, Hubbard RE (2004) Structure-activity relationships in purine-based inhibitor binding to HSP90 isoforms. CHEMISTRY & BIOLOGY, 11 (6). pp. 775-785. ISSN 1074-5521

Pors K, Paniwnyk Z, Ruparelia KC, Teesdale-Spittle PH, Hartley JA, Kelland LR, Patterson LH (2004) Synthesis and biological evaluation of novel chloroethylaminoanthraquinones with potent cytotoxic activity against cisplatin-resistant tumor. JOURNAL OF MEDICINAL CHEMISTRY, 47 (7). pp. 1856-1859. ISSN 0022-2623

Judson, I. (2004) Systemic therapy of soft tissue sarcoma: an improvement in outcome. ANNALS OF ONCOLOGY, 15 (Supplement 4). iv193-iv196. ISSN 0923-7534

Niculescu-Duvaz I (2004) Technology evaluation: EMD-273063, EMD Lexigen. CURRENT OPINION IN MOLECULAR THERAPEUTICS, 6 (5). pp. 559-566. ISSN 1464-8431

Baird R, van Zyl-Smit RN, Iveson A, Duddy J, Rassam S (2004) Thalidomide is highly effective in a patient with meningeal acute myeloid leukaemia. LEUKEMIA & LYMPHOMA, 45 (1). pp. 179-181. ISSN 1042-8194

Livi L, Andreopoulou E, Shah N, Paiar F, Blake P, Judson I, Harmer C (2004) Treatment of uterine sarcoma at the Royal Marsden Hospital from 1974 to 1998. CLINICAL ONCOLOGY, 16 (4). pp. 261-268. ISSN 0936-6555

Reynisson J, McDonald E (2004) Tuning of hydrogen bond strength using substituents on phenol and aniline: A possible ligand design strategy. JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN, 18 (6). pp. 421-431. ISSN 0920-654X

Debiec-Rychter M, Dumez H, Judson I, Wasag B, Verweij J, Brown M, Dimitrijevic S, Sciot R, Stul M, Vranck H, Scurr M, Hagemeijer A, Van Glabbeke M, van Oosterom AT (2004) Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. EUROPEAN JOURNAL OF CANCER, 40 (5). pp. 689-695. ISSN 0959-8049

Hiorns, L. R., Bradshaw, T. D., Skelton, L. A., Yu, Q., Kelland, L. R., Leyland-Jones, B. (2004) Variation in RNA expression and genomic DNA content acquired during cell culture. BRITISH JOURNAL OF CANCER, 90 (2). pp. 476-482. ISSN 0007-0920

Brooks TD, Wang SMW, Brunner N, Charlton PA (2004) XR5967, a novel modulator of plasminogen activator inhibitor-1 activity, suppresses tumor cell invasion and angiogenesis in vitro. ANTI-CANCER DRUGS, 15 (1). pp. 37-44. ISSN 0959-4973

Bavetsias V, Clauss R, Henderson EA (2003) Antifolate chemistry: synthesis of 4-[N-[(6RS)-2-methyl-4-oxo-3,4,7,8-tetrahydro-6H-cyclopenta[g]quinazolin-6-yl]-N-(prop-2-ynyl)amino]benzoic acid via a (propargyl)Co2(CO)6+ complex. ORGANIC & BIOMOLECULAR CHEMISTRY, 1 (11). pp. 1943-1946. ISSN 1477-0520

Perez, J. M., Kelland, L. R., Montero, E. I., Boxall, F. E., Fuertes, M. A., Alonso, C., Navarro-Ranninger, C. (2003) Antitumor and cellular pharmacological properties of a novel platinum(IV) complex: trans- [PtCl2(OH)(2)(dimethylamine)(isopropylamine)]. MOLECULAR PHARMACOLOGY, 63 (4). pp. 933-944. ISSN 0026-895X

Leach, M. O., Brindle, K. M., Evelhoch, J. L., Griffiths, J. R., Horsman, M. R., Jackson, A., Jayson, G., Judson, I. R., Knopp, M. V., Maxwell, R. J., McIntyre, D., Padhani, A. R., Price, P., Rathbone, R., Rustin, G., Tofts, P. S., Tozer, G. M., Vennart, W., Waterton, J. C., Williams, S. R., Workman, P. (2003) Assessment of antiangiogenic and antivascular therapeutics using MRI: recommendations for appropriate methodology for clinical trials. BRITISH JOURNAL OF RADIOLOGY, 76 (Special Issue 1). S87-S91. ISSN 0007-1285

Reynisson J, Steenken S (2003) The complexation energy of the one-electron oxidized guanine-cytosine base pair and its parent system with small cations. A DFT-study. JOURNAL OF MOLECULAR STRUCTURE, 635 . pp. 133-139. ISSN 0022-2860

Perani, M., Ingram, C. J. E., Cooper, C. S., Garrett, M. D., Goodwin, G. H. (2003) Conserved SNH domain of the proto-oncoprotein SYT interacts with components of the human chromatin remodelling complexes, while the QPGY repeat domain forms homo-oligomers. ONCOGENE, 22 (50). pp. 8156-8167. ISSN 0950-9232

Welsh SJ, Hobbs S, Aherne GW (2003) Expression of uracil DNA glycosylase (UDG) does not affect cellular sensitivity to thymidylate synthase (TS) inhibition. EUROPEAN JOURNAL OF CANCER, 39 (3). pp. 378-387. ISSN 0959-8049

Maloney A, Clarke PA, Workman P (2003) Genes and proteins governing the cellular sensitivity to Hsp90 inhibitors: A mechanistic perspective. CURRENT CANCER DRUG TARGETS, 3 (5). pp. 331-341. ISSN 1568-0096

Barrie SE, Eno-Amooquaye E, Hardcastle A, Platt G, Richards J, Bedford D, Workman P, Aherne W, Mittnacht S, Garrett MD (2003) High-throughput screening for the identification of small-molecule inhibitors of retinoblastoma protein phosphorylation in cells. ANALYTICAL BIOCHEMISTRY, 320 (1). pp. 66-74. ISSN 0003-2697

Workman P (2003) How much gets there and what does it do?: the need for better pharmacokinetic and pharmacodynamic endpoints in contemporary drug discovery and development. CURRENT PHARMACEUTICAL DESIGN, 9 (11). pp. 891-902. ISSN 1381-6128

Ewart-Toland A, Briassouli P, de Koning JP, Mao JH, Yuan JW, Chan F, MacCarthy-Morrogh L, Ponder BAJ, Nagase H, Burn J, Ball S, Almeida M, Linardopoulos S, Balmain A (2003) Identification of Stk6/STK15 as a candidate low-penetrance tumor-susceptibility gene in mouse and human. NATURE GENETICS, 34 (4). pp. 403-412. ISSN 1061-4036

Collingridge, D. R., Glaser, M., Osman, S., Barthel, H., Hutchinson, O. C., Luthra, S. K., Brady, F., Bouchier-Hayes, L., Martin, S. J., Workman, P., Price, P., Aboagye, E. O. (2003) In vitro selectivity, in vivo biodistribution and tumour uptake of annexin V radiolabelled with a positron emitting radioisotope. BRITISH JOURNAL OF CANCER, 89 (7). pp. 1327-1333. ISSN 0007-0920

McSheehy PMJ, Troy H, Kelland LR, Judson IR, Leach MO, Griffiths JR (2003) Increased tumour extracellular pH induced by Bafilomycin A(1) inhibits tumour growth and mitosis in vivo and alters 5-fluorouracil pharmacokinetics. EUROPEAN JOURNAL OF CANCER, 39 (4). pp. 532-540. ISSN 0959-8049

Wang, R., Titley, J. C., Lu, Y. J., Summersgill, B. M., Bridge, J. A., Fisher, C., Shipley, J. (2003) Loss of 13q14-q21 and gain of 5p14-pter in the progression of leiomyosarcoma. MODERN PATHOLOGY, 16 (8). pp. 778-785. ISSN 0893-3952

Chung, Y. L., Troy, H., Banerji, U., Jackson, L. E., Walton, M I., Stubbs, M., Griffiths, J. R., Judson, I. R., Leach, M. O., Workman, P., Ronen, S. M. (2003) Magnetic resonance spectroscopic pharmacodynamic markers of the heat shock protein 90 inhibitor 17-allylamino,17- demethoxygeldanamycin (17AAG) in human colon cancer models. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 95 (21). pp. 1624-1633. ISSN 0027-8874

Clarke, P. A., George, M. L., Easdale, S., Cunningham, D., Swift, R. I,. Hill, M. E., Tait, D. M., Workman, P. (2003) Molecular pharmacology of cancer therapy in human colorectal cancer by gene expression profiling. CANCER RESEARCH, 63 (20). pp. 6855-6863. ISSN 0008-5472

Serafinowski PJ, Garland PB (2003) Novel photoacid generators for photodirected oligonucleotide synthesis. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 125 (4). pp. 962-965. ISSN 0002-7863

Spooner, R. A., Friedlos, F., Maycroft, K., Stribbling, S. M., Roussel, J., Brueggen, J., Stolz, B., O'Reilly, T., Wood, J., Matter, A., Marais, R., Springer, C. J. (2003) A novel vascular endothelial growth factor-directed therapy that selectively activates cytotoxic prodrugs. BRITISH JOURNAL OF CANCER, 88 (10). pp. 1622-1630. ISSN 0007-0920

Workman P (2003) Overview: translating Hsp90 biology into Hsp90 drugs. CURRENT CANCER DRUG TARGETS, 3 (5). pp. 297-300. ISSN 1568-0096

Beale, P., Judson, I., O'Donnell, A., Trigo, J., Rees, C., Raynaud, F., Turner, A., Simmons, L., Etterley, L. (2003) A phase I clinical and pharmacological study of cis-diamminedichloro(2-methylpyridine) platinum II (AMD473). BRITISH JOURNAL OF CANCER, 88 (7). pp. 1128-1134. ISSN 0007-0920

Seddon, B. M., Payne, G.S, Simmons, L., Ruddle, R., Grimshaw, R., Tan, S., Turner, A., Raynaud, F., Halbert, G., Leach, M. O., Judson, I., Workman, P. (2003) A phase I study of SR-4554 via intravenous administration for noninvasive investigation of tumor hypoxia by magnetic resonance spectroscopy in patients with malignancy. CLINICAL CANCER RESEARCH, 9 (14). pp. 5101-5112. ISSN 1078-0432

Rees, C., Beale, P., Trigo, J. M., Mitchell, F., Jackman, A., Smith, R., Douglass, E., Judson, I. (2003) Phase I trial of ZD9331, a nonpolyglutamatable thymidylate synthase inhibitor, given as a 5-day continuous infusion to patients with refractory solid malignancies. CLINICAL CANCER RESEARCH, 9 (6). pp. 2049-2055. ISSN 1078-0432

Plummer, R., Rees, C., Hughes, A., Beale, P., Highley, M., Trigo, J., Gokul, S., Judson, I., Calvert, H., Jackman, A., Mitchell, F., Smith, R., Douglass, E. (2003) A phase I trial of ZD9331, a water-soluble, nonpolyglutamatable, thymidylate synthase inhibitor. CLINICAL CANCER RESEARCH, 9 (4). pp. 1313-1322. ISSN 1078-0432

Johnston SRD, Hickish T, Ellis P, Houston S, Kelland L, Dowsett M, Salter J, Michiels B, Perez-Ruixo JJ, Palmer P, Howes A (2003) Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor, R115777, in advanced breast cancer. JOURNAL OF CLINICAL ONCOLOGY, 21 (13). pp. 2492-2499. ISSN 0732-183X

Seddon, B. M., Workman, P. (2003) The role of functional and molecular imaging in cancer drug discovery and development. BRITISH JOURNAL OF RADIOLOGY, 76 (Special Issue 2). S128-S138. ISSN 0007-1285

Aherne W, Workman P (2003) Screening for novel anticancer drugs in an academic environment: the right time and the right place?. SCREENING: TRENDS IN DRUG DISCOVERY, 4 . pp. 44-47.

Theti, D. S., Bavetsias, V., Skelton, L. A., Titley, J., Gibbs, D., Jansen, G., Jackman, A. L. (2003) Selective delivery of CB300638, a cyclopenta[g]quinazoline-based thymidylate synthase inhibitor into human tumor cell lines overexpressing the alpha-isoform of the folate receptor. CANCER RESEARCH, 63 (13). pp. 3612-3618. ISSN 0008-5472

Niculescu-Duvaz, D., Niculescu-Duvaz, I., Friedlos, F., Martin, J., Lehouritis, P., Marais, R., Springer, C. J. (2003) Self-immolative nitrogen mustards prodrugs cleavable by carboxypeptidase G2 (CPG2) showing large cytotoxicity differentials in GDEPT. JOURNAL OF MEDICINAL CHEMISTRY, 46 (9). pp. 1690-1705. ISSN 0022-2623

O'Donnell, A., Punt, C. J. A., Judson, I., van Maanen, L., Suttle, A. B., Ertel, P., Beale, P. (2003) A study to evaluate the pharmacokinetics of oral 5-fluorouracil and eniluracil after concurrent administration to patients with refractory solid tumours and varying degrees of renal impairment (FUMA1005). CANCER CHEMOTHERAPY AND PHARMACOLOGY, 51 (1). pp. 58-66. ISSN 0344-5704

Pearson VC, Ferguson J, Rogers PM, Kelland LR, Robin DJ (2003) Synthesis and antimelanoma activity of tertiary amide analogues of N-acetyl-4-S-cysteaminylphenol. ONCOLOGY RESEARCH, 13 (11). pp. 503-512. ISSN 0965-0407

Owen C, James K, Sampson L, Ahmed S (2003) Synthesis and biochemical evaluation of some novel benzoic acid based esters as potential inhibitors of oestrone sulphatase. JOURNAL OF PHARMACY AND PHARMACOLOGY, 55 (1). pp. 85-93. ISSN 0022-3573

Modjtahedi H, Moscatello DK, Box G, Green M, Shotton C, Lamb DJ, Reynolds LJ, Wong AJ, Dean CJ, Thomas H, Eccles SA (2003) Targeting of cells expressing wild-type EGFR and type-III mutant EGFR (EGFRVIII) by anti-EGFR MAb ICR62: A two-pronged attack for tumour therapy. INTERNATIONAL JOURNAL OF CANCER, 105 (2). pp. 273-280. ISSN 0020-7136

Farrugia, D. C., Ford, H. E. R., Cunningham, D., Danenberg, K. D., Danenberg, P. V., Brabender, J., McVicar, A. D., Aherne, G. W., Hardcastle, A., McCarthy, K., Jackman, A. L. (2003) Thymidylate synthase expression in advanced colorectal cancer predicts for response to raltitrexed. CLINICAL CANCER RESEARCH, 9 (2). pp. 792-801. ISSN 1078-0432

Harrison RJ, Cuesta J, Chessari G, Read MA, Basra SK, Reszka AP, Morrell J, Gowan SM, Incles CM, Tanious FA, Wilson WD, Kelland LR, Neidle S (2003) Trisubstituted acridine derivatives as potent and selective telomerase inhibitors. JOURNAL OF MEDICINAL CHEMISTRY, 46 (21). pp. 4463-4476. ISSN 0022-2623

O-Charoenrat P, Pillai G, Patel S, Fisher C, Archer D, Eccles S, Rhys-Evans P (2003) Tumour thickness predicts cervical nodal metastases and survival in early oral tongue cancer. ORAL ONCOLOGY, 39 (4). pp. 386-390. ISSN 1368-8375

Tutton MG, George ML, Eccles SA, Burton S, Swift RI, Abulafi AM (2003) Use of plasma MMP-2 and MMP-9 levels as a surrogate for tumour expression in colorectal cancer patients. INTERNATIONAL JOURNAL OF CANCER, 107 (4). pp. 541-550. ISSN 0020-7136

Livi L, Paiar F, Shah N, Blake P, Villanucci A, Amunni G, Barca R, Judson I, Lodge N, Meldolesi E, Simontacchi G, Piperno G, Galardi A, Scoccianti S, Biti GP, Harmer C (2003) Uterine sarcoma: Twenty-seven years of experience. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 57 (5). pp. 1366-1373. ISSN 0360-3016

Asad Y, Cropp G, Adams A, O'Donnell A, Raynaud F, Judson I, Workman P (2003) Validation of liquid chromatography assay for the quantitation of (Z)-3-[2,4-dimethyl-5-(2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-1H-pyrrol-3-yl]propionic acid (SU006668) in human plasma and its application to a phase I clinical trial. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 785 (1). pp. 175-186. ISSN 1570-0232

Cowen, R. L., Patterson, A. V., Telfer, B. A., Airley, R. E., Hobbs, S., Phillips, R. M., Jaffar, M., Stratford, I. J., Williams, K. J. (2003) Viral delivery of P450 reductase recapitulates the ability of constitutive overexpression of reductase enzymes to potentiate the activity of mitomycin C in human breast cancer xenografts. MOLECULAR CANCER THERAPEUTICS, 2 (9). pp. 901-909. ISSN 1535-7163

Balda, M. S., Garrett, M. D., Matter, K. (2003) The ZO-1-associated Y-box factor ZONAB regulates epithelial cell proliferation and cell density. JOURNAL OF CELL BIOLOGY, 160 (3). pp. 423-432. ISSN 0021-9525

Panaretou, B., Siligardi, G., Meyer, P., Maloney, A., Sullivan, J. K., Singh, S., Millson, S. H., Clarke, P. A., Naaby-Hansen, S., Stein, R., Cramer, R., Mollapour, M., Workman, P., Piper, P. W., Pearl, L. H., Prodromou, C. (2002) Activation of the ATPase activity of Hsp90 by the stress-regulated cochaperone Aha1. MOLECULAR CELL, 10 (6). pp. 1307-1318. ISSN 1097-2765

Condie A, Powles RL, Hudson CD, Shepherd V, Bevan S, Yuille MR, Houlston RS (2002) Analysis of the Fanconi anaemia complentation group A gene in acute myeloid leukaemia. LEUKEMIA & LYMPHOMA, 43 (9). pp. 1849-1853. ISSN 1042-8194

Heald RA, Modi C, Cookson JC, Hutchinson I, Laughton CA, Gowan SM, Kelland LR, Stevens MFG (2002) Antitumor polycyclic acridines. 8. Synthesis and telomerase-inhibitory activity of methylated pentacyclic acridinium salts. JOURNAL OF MEDICINAL CHEMISTRY, 45 (3). pp. 590-597. ISSN 0022-2623

Al-Saffar, N. M. S., Titley, J. C., Robertson, D., Clarke, P. A., Jackson, L. E., Leach, M. O., Ronen, S. M. (2002) Apoptosis is associated with triacyglycerol accumulation in Jurkat T-cells. BRITISH JOURNAL OF CANCER, 86 (6). pp. 963-970. ISSN 0007-0920

Aherne GW, Rowlands MG, Stimson L, Workman P (2002) Assays for the identification and evaluation of histone acetyltransferase inhibitors. METHODS, 26 (3). pp. 245-253. ISSN 1046-2023

Coley HM, Sargent JM, Williamson CJ, Titley J, Scheper RJ, Gregson SE, Elgie AW, Lewandowicz GM, Taylor CG (2002) Assessment of the classical MDR phenotype in epithelial ovarian carcinoma using primary cultures: A feasibility study. ANTICANCER RESEARCH, 22 (1A). pp. 69-74. ISSN 0250-7005

O-charoenrat P, Rhys-Evans PH, Archer DJ, Eccles SA (2002) C-erbB receptors in squamous cell carcinomas of the head and neck: clinical significance and correlation with matrix metalloproteinases and vascular endothelial growth factors. EUROPEAN JOURNAL OF CANCER. PART B, ORAL ONCOLOGY, 38 (1). pp. 73-80. ISSN 0964-1955

Workman, P. (2002) Cancer - 21st century solutions. BIOTECHNOLOGY INVESTMENT TODAY .

Workman P (2002) Challenges of PK/PD measurements in modern drug development. EUROPEAN JOURNAL OF CANCER, 38 (16). pp. 2189-2193. ISSN 0959-8049

Pappenberger G, Wilsher JA, Roe SM, Counsell DJ, Willison KR, Pearl LH (2002) Crystal structure of the CCT gamma apical domain: Implications for substrate binding to the eukaryotic cytosolic chaperonin. JOURNAL OF MOLECULAR BIOLOGY, 318 (5). pp. 1367-1379. ISSN 0022-2836

Chapple, J. P., Hardcastle, A. J., Grayson, C., Willison, K. R., Cheetham, M. E. (2002) Delineation of the plasma membrane targeting domain of the X-linked retinitis pigmentosa protein RP2. INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 43 (6). pp. 2015-2020. ISSN 0146-0404

Bavetsias V, Skelton LA, Yafai F, Mitchell F, Wilson SC, Allan B, Jackman AL (2002) The design and synthesis of water-soluble analogues of CB30865, a quinazolin-4-one-based antitumor agent. JOURNAL OF MEDICINAL CHEMISTRY, 45 (17). pp. 3692-3702. ISSN 0022-2623

Ahmed S, James K, Owen CP, Patel CK (2002) Design, synthesis and biochemical evaluation of AC ring mimics as novel inhibitors of the enzyme estrone sulfatase (ES). BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 12 (10). pp. 1343-1346. ISSN 0960-894X

Huang, G. C., Hobbs, S., Walton, M., Epstein, R. J. (2002) Dominant negative knockout of p53 abolishes ErbB2-dependent apoptosis and permits growth acceleration in human breast cancer cells. BRITISH JOURNAL OF CANCER, 86 (7). pp. 1104-1109. ISSN 0007-0920

Plows, D., Briassouli, P., Owen, C., Zoumpourlis, V., Garrett, M. D., Pintzas, A. (2002) Ecdysone-inducible expression of oncogenic Ha-Ras in NIH 3T3 cells leads to transient nuclear localization of activated extracellular signal-regulated kinase regulated by mitogen-activated protein kinase phosphatase-1. BIOCHEMICAL JOURNAL, 362 (Part 2). pp. 305-315. ISSN 0264-6021

Garland, P. B., Serafinowski, P. J. (2002) Effects of stray light on the fidelity of photodirected oligonucleotide array synthesis. NUCLEIC ACIDS RESEARCH, 30 (19). ISSN 0305-1048

Smith V, Hobbs S, Court W, Eccles S, Workman P, Kelland LR (2002) ErbB2 overexpression in an ovarian cancer cell line confers sensitivity to the HSP90 inhibitor geldanamycin. ANTICANCER RESEARCH, 22 (4). pp. 1993-1999. ISSN 0250-7005

Smith, V., Rowlands, M. G., Barrie, E., Workman, P., Kelland, L. R. (2002) Establishment and characterization of acquired resistance to the farnesyl protein transferase inhibitor R115777 in a human colon cancer cell line. CLINICAL CANCER RESEARCH, 8 (6). pp. 2002-2009. ISSN 1078-0432

Ahmed S, Owen CP, James K, Patel CK, Sampson L (2002) Evidence for the mechanism of the irreversible inhibition of oestrone sulphatase (ES) by aminosulphonate based compounds. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 80 (4-5). pp. 429-440. ISSN 0960-0760

Vlachou M, Tsotinis A, Kelland LR, Thurston DE (2002) An expeditious synthesis of cytotoxic pyrroloisoquinoline derivatives. Structure-activity comparative studies with isomeric pyrroloquinolines. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 17 (3). pp. 139-143. ISSN 0928-0987

Aherne, G. W., McDonald, E., Workman, P. (2002) Finding the needle in the haystack: why high-throughput screening is good for your health. BREAST CANCER RESEARCH, 4 (4). pp. 148-154. ISSN 1465-5411

Gowan, S. M., Harrison, J. R., Patterson, L., Valenti, M., Read, M. A., Neidle, S., Kelland, L. R. (2002) A G-quadruplex-interactive potent small molecule inhibitor of telomerase exhibiting in vitro and in vivo antitumour activity. MOLECULAR PHARMACOLOGY, 61 (5). pp. 1154-1162. ISSN 0026-895X

Svancarova, L., Blay, J. Y., Judson, I. R., van Hoesel, Q. G. C. M., van Oosterom, A. T., le Cesne, A., Keizer, H. J., Hermans, C., van Glabbeke, M., Verweij, J., Hogendoorn, P. C. W., Nielsen, O. S. (2002) Gemcitabine in advanced adult soft-tissue sarcomas. A phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. EUROPEAN JOURNAL OF CANCER, 38 (4). pp. 556-559. ISSN 0959-8049

Gebska, M. A., Titley, I., Paterson, H. F., Morilla, R. M., Davies, D. C., Gruszka-Westwood, A. M., Kakkar, V. V., Eccles, S., Scully, M. F. (2002) High-affinity binding sites for heparin generated on leukocytes during apoptosis arise from nuclear structures segregated during cell death. BLOOD, 99 (6). pp. 2221-2227. ISSN 0006-4971

Patel S, Turner P, Stubberfield C, Barry E, Rohlff CR, Stamps A, Tyson K, Box G, Eccles S, Page MJ (2002) Hyaluronidase gene profiling and role of hyal-1 overexpression in an orthotopic model of prostate cancer. INTERNATIONAL JOURNAL OF CANCER, 97 (4). pp. 416-424. ISSN 0020-7136

Ahmed S, James K, Owen CP, Patel CK, Sampson L (2002) The mechanism of the irreversible inhibition of estrone sulfatase (ES) through the consideration of a range of methane- and amino-sulfonate-based compounds. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 12 (9). pp. 1279-1282. ISSN 0960-894X

Vaughan K, Wilman DEV, Wheelhouse RT, Stevens MFG (2002) A N-15 NMR investigation of a series of benzotriazinones and related antitumour heterocycles. MAGNETIC RESONANCE IN CHEMISTRY, 40 (4). pp. 300-302. ISSN 0749-1581

Serafinowski, P. J., Brown, C. A. (2002) New method for the preparation of 3'- and 2'-O-phosphoramidites of 2'- and 3'-difluoromethyluridine derivatives. NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS, 21 (1). pp. 1-13. ISSN 1525-7770

Vlachou M, Tsotinis A, Kelland LR, Thurston DE (2002) A new ring-forming methodology for the synthesis of bioactive pyrroloquinoline derivatives. HETEROCYCLES, 57 (1). pp. 129-133. ISSN 0385-5414

Rogers PM, Beale PJ, Al-Moundhri M, Boxall F, Patterson L, Valenti M, Raynaud F, Hobbs S, Johnston S, Kelland LR (2002) Overexpression of BCLXL in a human ovarian carcinoma cell line: paradoxic effects on chemosensitivity in vitro versus in vivo. INTERNATIONAL JOURNAL OF CANCER, 97 (6). pp. 858-863. ISSN 0020-7136

Ford, H. E. R., Mitchell, F., Cunningham, D., Farrugia, D. C., Hill, M. E., Rees, C., Calvert, H., Judson, I. R., Jackman, A. L. (2002) Patterns of elevation of plasma 2'-deoxyuridine, a surrogate marker to thymidylate synthase (TS) inhibition, after administration of two different schedules of 5-flourouracil and the specific TS inhibitors raltitrexed (tomudex) and ZD93311. CLINICAL CANCER RESEARCH, 8 (1). pp. 103-109. ISSN 1078-0432

Holland RJ, Hardcastle IR, Dick AG, Nutley BP, Hayes A, Jarman M (2002) Pentafluoronitrobenzene a novel scaffold for the solid-phase synthesis of 2,4,6-substituted-3,5-difluoronitrobenzene libraries. TETRAHEDRON LETTERS, 43 (4). pp. 719-721. ISSN 0040-4039

Workman P (2002) Pharmacogenomics in cancer drug discovery and development: inhibitors of the Hsp90 molecular chaperone. CANCER DETECTION AND PREVENTION, 26 (6). pp. 405-410. ISSN 0361-090X

Francis, R. J., Sharma, S. K., Springer, C., Green, A. J., Hope-Stone, L. D., Sena, L., Martin, J., Adamson, K. L., Robbins, A., Gumbrell, L., O'Malley, D., Tsiompanou, E., Shahbakhti, H., Webley, S., Hochhauser, D., Hilson, A. J., Blakey, D., Begent, R. H. J. (2002) A phase I trial of antibody directed enzyme prodrug therapy (ADEPT) in patients with advanced colorectal carcinoma or other CEA producing tumours. BRITISH JOURNAL OF CANCER, 87 (6). pp. 600-607. ISSN 0007-0920

Ashcroft, M., Ludwig, R. L., Woods, D. B., Copeland, T. D., Weber, H. O., MacRae, E. J., Vousden, K. H. (2002) Phosphorylation of HDM2 by Akt. ONCOGENE, 21 (13). pp. 1955-1962. ISSN 0950-9232

George ML, Tutton MG, Abulafi AM, Eccles SA, Swift RI (2002) Plasma basic fibroblast growth factor levels in colorectal cancer: A clinically useful assay? CLINICAL & EXPERIMENTAL METASTASIS, 19 (8). pp. 735-738. ISSN 0262-0898

Van Glabbeke M, Verweij J, Judson I, Nielsen OS (2002) Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas. EUROPEAN JOURNAL OF CANCER, 38 (4). pp. 543-549. ISSN 0959-8049

Jackman, A. L., Melin, C. J., Kimbell, R., Brunton, L., Aherne, G. W., Theti, D. S., Walton, M. (2002) A rationale for the clinical development of the thymidylate synthase inhibitor ZD9331 in ovarian and other solid tumours. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 1587 (2-3). pp. 215-223. ISSN 0925-4439

Sharp SY, O'Neill CF, Rogers P, Boxall FE, Kelland LR (2002) Retention of activity by the new generation platinum agent AMD0473 in four human tumour cell lines possessing acquired resistance to oxaliplatin. EUROPEAN JOURNAL OF CANCER, 38 (17). pp. 2309-2315. ISSN 0959-8049

O-Charoenrat P, Rhys-Evans PH, Modjtahedi H, Eccles SA (2002) The role of c-erbB receptors and ligands in head and neck squamous cell carcinoma. EUROPEAN JOURNAL OF CANCER. PART B, ORAL ONCOLOGY, 38 (7). pp. 627-640. ISSN 0964-1955

Rogers P, Boxall FE, Allott CP, Stephens TC, Kelland LR (2002) Sequence-dependent synergism between the new generation platinum agent ZD0473 and paclitaxel in cisplatin-sensitive and -resistant human ovarian carcinoma cell lines. EUROPEAN JOURNAL OF CANCER, 38 (12). pp. 1653-1660. ISSN 0959-8049

Brader S, O-Charoenrat P, Court W, Box G, Workman P, Eccles S (2002) Signalling pathways in afferent and efferent arms of angiogenesis induced by activation of c-erbB receptors. PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 43 . p. 33. ISSN 0197-016X

Fyfe D, Raynaud F, Langley RE, Newell DR, Halbert G, Gardner C, Clayton K, Woll PJ, Judson I, Carmichael J (2002) A study of amsalog (CI-921) administered orally on a 5-day schedule, with bioavailability and pharmacokinetically guided dose escalation. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 49 (1). pp. 1-6. ISSN 0344-5704

Berry, J. M., Howard, P. W., Kelland, L. R., Thurston, D. E. (2002) Synthesis and biological evaluation of an N10-Psec substituted pyrrolo[2,1-c][1,4]benzodiazepine prodrug. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 12 (10). pp. 1413-1416. ISSN 0960-894X

Holland RJ, Hardcastle IR, Jarman M (2002) Synthesis of 6,8-substituted-5,7-difluoro-3,4-dihydro-1H-quinoxalin-2-ones via reductive cyclisation of 2,4,6-substituted-3,5-difluoronitrobenzenes. TETRAHEDRON LETTERS, 43 (36). pp. 6435-6437. ISSN 0040-4039

Heyes, J. A., Niculescu-Duvaz, D., Cooper, R. G., Springer, C. J. (2002) Synthesis of novel cationic lipids: Effect of structural modification on the efficiency of gene transfer. JOURNAL OF MEDICINAL CHEMISTRY, 45 . pp. 99-114. ISSN 0022-2623

O-Charoenrat, P., Rhys-Evans, P., Eccles, S. (2002) A synthetic matrix metalloproteinase inhibitor prevents squamous carcinoma cell proliferation by interfering with epidermal growth factor receptor autocrine loops. INTERNATIONAL JOURNAL OF CANCER, 100 (5). pp. 527-533. ISSN 0020-7136

Friedlos, F., Davies, L., Scanlon, I., Ogilvie, L. M., Martin, J., Stribbling, S. M., Spooner, R. A., Niculescu-Duvaz, I., Marais, R., Springer, C. J. (2002) Three new prodrugs for suicide gene therapy using carboxypeptidase G2 elicit bystander efficacy in two xenograft models. CANCER RESEARCH, 62 (6). pp. 1724-1729. ISSN 0008-5472

van Oosterom AT, Judson IR, Verweij J, Stroobants S, Dumez H, di Paola ED, Sciot R, Van Glabbeke M, Dimitrijevic S, Nielsen OS (2002) Update of phase I study of imatinib (ST1571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group. EUROPEAN JOURNAL OF CANCER, 38 (Supplement 5). S83-S87. ISSN 0959-8049

Liu, D., Hutchinson, O. C., Osman, S., Price, P., Workman, P., Aboagye, E. O. (2002) Use of radiolabelled choline as a pharmacodynamic marker for the signal transduction inhibitor geldanamycin. BRITISH JOURNAL OF CANCER, 87 (7). pp. 783-789. ISSN 0007-0920

Seddon, B. M., Maxwell, R. J., Honess, D. J., Grimshaw, R., Raynaud, F., Tozer, G. M., Workman, P. (2002) Validation of the fluorinated 2-nitroimidazole SR-4554 as a noninvasive hypoxia marker detected by magnetic resonance spectroscopy. CLINICAL CANCER RESEARCH, 8 (7). pp. 2323-2335. ISSN 1078-0432

Webley, S. D., Welsh, S. J., Jackman, A. L., Aherne, G. W. (2001) The ability to accumulate deoxyuridine triphosphate and cellular response to thymidylate synthase (TS) inhibition. BRITISH JOURNAL OF CANCER, 85 (3). pp. 446-452. ISSN 0007-0920

Andreyev, H. J. N., Ross, P. J., Cunningham, D., Clarke, P. A. (2001) Antisense treatment directed against mutated Ki-ras in human colorectal adenocarcinoma. GUT, 48 (2). pp. 230-237. ISSN 0017-5749

Spooner, R. A., Maycroft, K. A., Paterson, H., Friedlos, F., Springer, C. J., Marais, R. (2001) Appropriate subcellular localisation for prodrug-activating enzymes has important consequences for suicide gene therapy. INTERNATIONAL JOURNAL OF CANCER, 93 (1). pp. 123-130. ISSN 0020-7136

Fry, D. W., Bedford, D. C., Harvey, P. H., Fritsch, A., Keller, P. R., Wu, Z. P., Dobrusin, E., Leopold, W. R., Fattaey, A., Garrett, M. D. (2001) Cell cycle and biochemical effects of PD 0183812 - a potent inhibitor of the cyclin D-dependent kinases CDK4 and CDK6. JOURNAL OF BIOLOGICAL CHEMISTRY, 276 (20). pp. 16617-16623. ISSN 0021-9258

Garrett MD (2001) Cell cycle control and cancer. CURRENT SCIENCE, 81 (5). pp. 515-522. ISSN 0011-3891

Smith, V., Raynaud, F., Workman, P., Kelland, L. R. (2001) Characterization of a human colorectal carcinoma cell line with acquired resistance to flavopiridol. MOLECULAR PHARMACOLOGY, 60 (5). pp. 885-893. ISSN 0026-895X

O-charoenrat P, Rhys-Evans P, Eccles SA (2001) Characterization of ten newly-derived human head and neck squamous carcinoma cell lines with special reference to c-erbB proto-oncogene expression. ANTICANCER RESEARCH, 21 (3B). pp. 1953-1963. ISSN 0250-7005

Bavetsias, V., Marriott, J. H., Thethi, D. S., Melin, J. C., Wilson, S. C., Jackman, A. L. (2001) Cyclopental[g]quinazoline-based antifolates: the effect of the chirality at the 6-position on the inhibition of thymidylate synthase (TS). BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 11 (23). pp. 3015-3017. ISSN 0960-894X

Summersgill BM, Jafer O, Wand R, Goker H, Niculescu-Duvaz I, Huddart R, Shipley J (2001) Definition of chromosome aberrations in testicular germ cell tumor cell lines by 24-color karyotyping and complementary molecular cytogenetic analyses. CANCER GENETICS AND CYTOGENETICS, 128 (2). pp. 120-129. ISSN 0165-4608

Gregson SJ, Howard PW, Hartley JA, Brooks NA, Adams LJ, Jenkins TC, Kelland LR, Thurston DE (2001) Design, synthesis, and evaluation of a novel pyrrolobenzodiazepine DNA-interactive agent with highly efficient cross-linking ability and potent cytotoxicity. JOURNAL OF MEDICINAL CHEMISTRY, 44 (5). pp. 737-748. ISSN 0022-2623

O-charoenrat P, Rhys-Evans PH, Eccles SA (2001) Expression of matrix metalloproteinases and their inhibitors correlates with invasion and metastasis in squamous cell carcinoma of the head and neck. ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY, 127 (7). pp. 813-820. ISSN 0886-4470

O-charoenrat, P., Rhys-Evans, P., Eccles, S. A. (2001) Expression of vascular endothelial growth factor family members in head and neck squamous cell carcinoma correlates with lymph node metastasis. CANCER CYTOPATHOLOGY, 92 (3). pp. 556-568. ISSN 0008-543X

Johnston, S. R. D., Kelland, L. R. (2001) Farnesyl transferase inhibitors - a novel therapy for breast cancer. ENDOCRINE-RELATED CANCER, 8 (3). pp. 227-235. ISSN 1351-0088

Clarke, P. A., te Poele, R., Wooster, R., Workman, P. (2001) Gene expression microarray analysis in cancer biology, pharmacology, and drug development: progress and potential. BIOCHEMICAL PHARMACOLOGY, 62 (10). pp. 1311-1336. ISSN 0006-2952

Orr RM (2001) GTI-2040 lorus therapeutics. CURRENT OPINION IN INVESTIGATIONAL DRUGS (LONDON, ENGLAND: 2000), 2 (10). pp. 1462-1466. ISSN 1472-4472

Cocker, H. A., Hobbs, S. M., Tiffin, N., Pritchard-Jones, K., Pinkerton, C. R., Kelland, L. R. (2001) High levels of the MDM2 oncogene in paediatric rhabdomyosarcoma cell lines may confer multidrug resistance. BRITISH JOURNAL OF CANCER, 85 (11). pp. 1746-1752. ISSN 0007-0920

Turlais F, Hardcastle A, Rowlands M, Newbatt Y, Bannister A, Kouzarides T, Workman P, Aherne GW (2001) High-throughput screening for identification of small molecule inhibitors of histone acetyltransferases using scintillating microplates (FlashPlate). ANALYTICAL BIOCHEMISTRY, 298 (1). pp. 62-68. ISSN 0003-2697

Cocker, H. A., Tiffin, N., Pritchard-Jones, K., Pinkerton, C. R., Kelland, L. R. (2001) In vitro prevention of the emergence of multidrug resistance in a pediatric rhabdomyosarcoma cell line. CLINICAL CANCER RESEARCH, 7 (10). pp. 3193-3198. ISSN 1078-0432

Ross, P. J., George, M., Cunningham, D., Di Stefano, F., Andreyev, H. J. N., Workman, P., Clarke, P. A. (2001) Inhibition of kirsten-ras expression in human colorectal cancer using rationally selected kirsten-ras antisense oligonucleotides. MOLECULAR CANCER THERAPEUTICS, 1 (1). pp. 29-41. ISSN 1535-7163

Hostein, I., Robertson, D., Di Stefano, D., Workman, P., Clarke, P. A. (2001) Inhibition of signal transduction by the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin results in cytostasis and apoptosis. CANCER RESEARCH, 61 (10). pp. 4003-4009. ISSN 0008-5472

Bailey SM, Lewis AD, Patterson LH, Fisher GR, Knox RJ, Workman P (2001) Involvement of NADPH: cytochrome P450 reductase in the activation of indoloquinone EO9 to free radical and DNA damaging species. BIOCHEMICAL PHARMACOLOGY, 62 (4). pp. 461-468. ISSN 0006-2952

Andreyev, H. J. N., Norman, A. R., Cunningham, D., Oates, J., Dix, B. R., Iacopetta, B. J., Young, J., Walsh, T., Ward, R., Hawkins, N., Beranek, M., Jandik, P., Benamouzig, R., Jullian, E., Laurent-Puig, P., Olschwang, S., Muller, O., Hoffmann, I., Rabes, H. M., Zietz, C., Troungos, C., Valavanis, C., Yuen, S. T., Ho, J. W. C., Croke, C. T., O'Donoghue, D. P., Giaretti, W., Rapallo, A., Russo, A., Bazan, V., Tanaka, M., Omura, K., Azuma, T., Ohkusa, T., Fujimori, T., Ono, Y., Pauly, M., Faber, C., Glaesener, R., de Goeij, A. F. P. M., Arends, J. W., Andersen, S. N., Lovig, T., Breivik, J., Gaudernack, G., Clausen, O. P. F., De Angelis, P., Meling, G. I., Rognum, T. O., Smith, R., Goh, H. S., Font, A., Rosell, R., Sun, X. F., Zhang, H., Benhattar, J., Losi, L., Lee, J. Q., Wang, S. T., Clarke, P. A., Bell, S., Quirke, P., Bubb, V. J., Piris, J., Cruickshank, N. R., Morton, D., Fox, J. C., Al-Mulla, F., Lees, N., Hall, C. N., Snary, D., Wilkinson, K., Dillon, D., Costa, J., Pricolo, V. E., Finkelstein, S. D., Thebo, J. S., Senagore, A. J., Halter, S. A., Wadler, S., Malik, S., Krtolica, K., Urosevic, N. (2001) Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study. BRITISH JOURNAL OF CANCER, 85 (5). pp. 692-696. ISSN 0007-0920

Seddon BM, Honess DJ, Vojnovic B, Tozer GM, Workman P (2001) Measurement of tumor oxygenation: In vivo comparison of a luminescence fiber-optic sensor and a polarographic electrode in the P22 tumor. RADIATION RESEARCH, 155 (6). pp. 837-846. ISSN 0033-7587

van der Wilt, C. L., Backus, H. H. J., Smid, K., Comijn, L., Veerman, G., Wouters, D., Voorn, D. A., Priest, D. G., Bunni, M. A., Mitchell, F., Jackman, A. L., Jansen, G., Peters, G. J. (2001) Modulation of both endogenous folates and thymidine enhance the therapeutic efficacy of thymidylate synthase inhibitors. CANCER RESEARCH, 61 (9). pp. 3675-3681. ISSN 0008-5472

Mann J, Baron A, Opoku-Boahen Y, Johansson E, Parkinson G, Kelland LR, Neidle S (2001) A new class of symmetric bisbenzimidazole-based DNA minor groove-binding agents showing antitumor activity. JOURNAL OF MEDICINAL CHEMISTRY, 44 (2). pp. 138-144. ISSN 0022-2623

George ML, Dzik-Jurasz ASK, Padhani AR, Brown G, Husband J, Hill ME, Cunningham D, Tait DM, Swift RI, Eccles SA (2001) Non-invasive methods of assessing angiogenesis and their value in predicting response to treatment in colorectal cancer. BRITISH JOURNAL OF SURGERY, 88 (12). pp. 1628-1636. ISSN 0007-1323

Hegmans A, Qu Y, Kelland LR, Roberts JD, Farrell N (2001) Novel approaches to polynuclear platinum pro-drugs. Selective release of cytotoxic platinum spermidine species through hydrolytic cleavage of carbamates. INORGANIC CHEMISTRY, 40 (24). pp. 6108-6114. ISSN 0020-1669

Bonn, D. (2001) Paul Workman - at the cutting edge of drug discovery. Interview. LANCET ONCOLOGY, 2 (2). pp. 113-118. ISSN 1470-2045

Aherne, G. W., Hardcastle, A., Ward, E., Dobinson, D., Crompton, T., Valenti, M., Brunton, L., Jackman, A. L. (2001) Pharmacokinetic/pharmacodynamic study of ZD9331, a nonpolyglutamatable inhibitor of thymidylate synthase, in a murine model following two curative administration schedules. CLINICAL CANCER RESEARCH, 7 (9). pp. 2923-2930. ISSN 1078-0432

Hardcastle IR, Moreno Barber A, Marriott JH, Jarman M (2001) Polymer-assisted solution-phase library synthesis of 4-alkoxy-2-hydroxy-3,5,6-trifluorobenzoic acids. TETRAHEDRON LETTERS, 42 (7). pp. 1363-1365. ISSN 0040-4039

Gowan, S. M., Heald, R., Stevens, M. F. G., Kelland, L. R. (2001) Potent inhibition of telomerase by small molecule pentacyclic acridines capable of interacting with G-quadruplexes. MOLECULAR PHARMACOLOGY, 60 (5). pp. 981-988. ISSN 0026-895X

Kelland, L. R., Smith, V., Valenti, M., Patterson, L., Clarke, P. A., Detre, S., End, D., Howes, A. J., Dowsett, M., Workman, P., Johnston, S. R. D. (2001) Preclinical antitumor activity and pharmacodynamic studies with the farnesylprotein transferase inhibitor R115777 in human breast cancer. CLINICAL CANCER RESEARCH, 7 (11). pp. 3544-3550. ISSN 1078-0432

Judson I, Radford JA, Harris M, Blay J, Van Hoesel Q, Le Cesne A, Van Oosterom AT, Clemons MJ, Kamby C, Hermans C, Whittaker J, Donato di Paola E, Verweij J, Nielsen S (2001) Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL(R)/ CAELYX(R)) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group. EUROPEAN JOURNAL OF CANCER, 37 (7). pp. 870-877. ISSN 0959-8049

Eccles SA (2001) The role of c-erbB2/HER2/neu in breast cancer progression and metastasis. JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA, 6 (4). pp. 393-406. ISSN 1083-3021

van Oosterom AT, Judson I, Verweij J, Stroobants S, di Paola ED, Dimitrijevic S, Martens M, Webb A, Sciot R, Van Glabbeke M, Silberman S, Nielsen OS (2001) Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. LANCET, 358 (9291). pp. 1421-1423. ISSN 0140-6736

Senter, P. D., Springer, C. J. (2001) Selective activation of anticancer prodrugs by monoclonal antibody-enzyme conjugates. ADVANCED DRUG DELIVERY REVIEWS, 53 (3). pp. 247-264. ISSN 0169-409X

Masters, J. R., Thomson, J. A., Daly-Burns, B., Reid, Y. A., Dirks, W. G., Packer, P., Toji, L. H., Ohno, T., Tanabe, H., Arlett, C. F., Kelland, L. R., Harrison, M., Virmani, A., Ward, T. H., Ayres, K. L., Debenham, P. G. (2001) Short tandem repeat profiling provides an international reference standard for human cell lines. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 98 (14). pp. 8012-8017. ISSN 0027-8424

Tutton MG, George M, Hill ME, Abulafi AM (2001) Solitary pancreatic metastasis from a primary colonic tumor detected by PET scan - Report of a case. DISEASES OF THE COLON & RECTUM, 44 (2). pp. 288-290. ISSN 0012-3706

Verweij J, Judson I, van Oosterom A (2001) STI571: a magic bullet? EUROPEAN JOURNAL OF CANCER, 37 (15). pp. 1816-1819. ISSN 0959-8049

Read, M., Harrison, R. J., Romagnoli, B., Tanious, F. A., Gowan, S. H., Reszka, A. P., Wilson, W. D., Kelland, L. R., Neidle, S. (2001) Structure-based design of selective and potent G quadruplex-mediated telomerase inhibitors. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 98 (9). pp. 4844-4849. ISSN 0027-8424

Lant NJ, McKeown P, Timoney MC, Kelland LR, Rogers PM, Robins DJ (2001) Synthesis and anti-melanoma activity of analogues of N-acetyl-4-S-cysteaminylphenol substituted with two methyl groups alpha to the nitrogen. ANTI-CANCER DRUG DESIGN, 16 (1). pp. 49-55. ISSN 0266-9536

Jolley, J. N., Yanovsky, A. I., Kelland, L. R., Nolan, K. B. (2001) Synthesis and antitumour activity of platinum(II) and platinum(IV) complexes containing ethylenediamine-derived ligands having alcohol, carboxylic acid and acetate substituents - Crystal and molecular structure of [(PtLCl2)-Cl-4]center dot H2O where L-4 is ethylenediamine-N,N '-diacetate. JOURNAL OF INORGANIC BIOCHEMISTRY, 83 (2-3). pp. 91-100. ISSN 0162-0134

Marriott, J. H., Aherne, G. W., Hardcastle, A., Jarman, M. (2001) Synthesis of certain 2'-deoxyuridine derivatives containing substituted phenoxy groups attached to C-5'; evaluation as potential dUTP analogues. NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS, 20 (9). pp. 1691-1704. ISSN 1525-7770

Serafinowski, P. J., Brown, C. A., Barnes, C. L. (2001) Synthesis of some 2 '- and 3 '-fluoroalkyl substituted nucleosides and oligonucleotides. NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS, 20 (4-7). pp. 921-925. ISSN 1525-7770

Gregson, S. J., Howard, P. W., Corcoran, K. E., Jenkins, T. C., Kelland, L. R., Thurston, D. E. (2001) Synthesis of the first example of a C2-C3/C2 '-C3 '-endo unsaturated pyrrolo[2,1-c][1,4]benzodiazepine dimer. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 11 (21). pp. 2859-2862. ISSN 0960-894X

Orr RM (2001) Technology evaluation: Fomivirsen, Isis pharmaceuticals Inc/CIBA vision. CURRENT OPINION IN MOLECULAR THERAPEUTICS, 3 (3). pp. 288-294. ISSN 1464-8431

George,, M. L., Tutton, M. G., Janssen, F., Arnaut, A., Abulafi, A. M., Eccles, S. A., Swift, R. I. (2001) VEGF-A, VEGF-C, and VEGF-D in colorectal cancer progression. NEOPLASIA, 3 (5). pp. 420-427. ISSN 1522-8002

Book

UNSPECIFIED (2004) Principles of Molecular Oncology. Humana Press Inc, Totowa, USA. ISBN 978-158829279-7

UNSPECIFIED, ed. (2004) Suicide Gene Therapy: Methods and Reviews. Methods in Molecular Medicine, 90 . Humana Press Inc, Totowa, USA. ISBN 978-089603971-1

Book Section

Box, C., Peak, J., Rogers, S., Eccles, S. (2008) EGFR signaling in invasion, angiogenesis and metastasis. In: EGFR Signaling Networks in Cancer Therapy. Cancer Drug Discovery and Development . Humana Press, Totowa, USA. ISBN 978-158829948-2

Workman, P., Burrows, F., Neckers, L., Rosen, N. (2007) Drugging the cancer chaperone HSP90 combinatorial therapeutic exploitation of oncogene addiction and tumor stress. In: Stress Responses in Biology and Medicine. Annals of the New York Academy of Sciences, 1113 . Blackwell Publishing, Oxford, pp. 202-216. ISBN 978-157331675-0

Eccles, S. A. (2007) Models for Breast Cancer. In: The Cancer Handbook (2nd ed.). John Wiley, Chichester, pp. 1067-1082. ISBN 978-047001852-1

Workman, P., Collins, I. (2007) Modern cancer drug discovery: integrating targets, technologies and treatments. In: Cancer Drug Design and Discovery. Academic Press, pp. 3-38. ISBN 978-012369448-5

Molife, R., Collins, I., Workman, P., Kaye, S. B. (2007) Rational drug design of small molecule anticancer agents: early clinical development. In: The Cancer Handbook (2nd ed.). Wiley, pp. 1216-1241. ISBN 978-047001852-1

Collins, I., Molife, R., Kaye, S. B., Workman, P. (2007) Rational drug design of small molecule anticancer agents: preclinical discovery. In: The Cancer Handbook. Wiley, pp. 1199-1215. ISBN 978-047001852-1

Workman, P. (2006) Drugging the cancer kinome: Progress and challenges in developing personalised molecular cancer therapeutics. In: Molecular Approaches to Controlling Cancer. Cold Spring Harbor Symposia on Quantitative Biology, 70 . Cold Spring Harbor Laboratory Press, Woodbury, USA, pp. 499-516. ISBN 978-087969773-0

Pacey, S., Banerji, U., Judson, I., Workman, P. (2006) Hsp90 inhibitors in the clinic. In: Molecular chaperones in health and disease. Springer, Berlin, Germany, pp. 331-358. ISBN 978-354025875-9

Sharp, S., Workman, P. (2006) Inhibitors of the HSP90 molecular chaperone: Current status. In: Advances in Cancer Research. Advances in Cancer Research, 95 . Elsevier Academic Press Inc, San Diego, USA, pp. 323-348. ISBN 978-012006695-7

Baird RD, Kaye SB. (2005) Drug resistance. A problem and possible solutions. In: Cancer Therapy: Molecular Targets in Tumour-Host Interactions. Taylor & Francis. ISBN 978-190493311-3

Eccles SA. (2005) General mechanisms of metastasis. In: Textbook of Bone Metastases. Wiley, Chichester, pp. 3-25. ISBN 978-047187742-4

Clarke PA, Powers M, Workman P. (2005) Inhibition of the molecular chaperone Hsp90 in cancer: consequences for the regulation of survival signalling and induction of cell death. In: Apoptosis and Cancer Therapy. Wiley, Chichester, pp. 933-965. ISBN 978-352731237-5

Orr RM, Dorr FA. (2004) Clinical Studies of Antisense Oligonucleotides for Cancer Therapy. In: UNSPECIFIED, (ed.) Antisense Therapeutics (2nd ed.). Humana Press, Totowa, USA, pp. 85-112. ISBN 978-158829205-6

Baird RD, Workman P (2004) Emerging molecular therapies: drugs affecting signal transduction. In: Principles of Molecular Oncology. Humana Press Inc., Totowa, USA, pp. 569-606. ISBN 978-158829279-7

te Poele R, Clarke PA, Workman P. (2004) Gene microarray technologies for cancer drug discovery and development. In: Molecular Cancer Therapeutics: Strategies for Drug Discovery and Development. John Wiley, pp. 142-148. ISBN 978-047143202-9

Banerji, U., Judson, I., Workman, P. (2004) Molecular targets. In: Handbook of Anticancer Pharmacokinetics and Pharmacodynamics. Cancer Drug Discovery and Development . Humana Press Inc, Totowa, New Jersey, pp. 1-28. ISBN 978-158829177-6

Workman P. (2004) Pharmacological intervention with multistep oncogenesis: potential role for HSP90 inhibitors. In: Cancer Chemoprevention Volume 1: Promising Cancer Chemoprevention Agents. Humana Press, Totowa, USA, pp. 325-338. ISBN 978-159259767-3

Niculescu-Duvaz, I., Springer, C. J. (2004) Suicide gene therapy. In: Principles of Molecular Oncology (2nd ed.). Humana Press Inc,, Totowa, New Jersey, pp. 675-694. ISBN 978-158829279-7

Niculescu-Duvaz, I., Springer, C. J. (2004) Suicide Gene Therapy. In: Cancer Gene Therapy. Humana Press, Totowa, USA, pp. 81-108. ISBN 978-158829213-1

Aherne W, Maloney A, Prodromou C, Rowlands MG, Hardcastle A, Boxall K, Clarke P, Walton MI, Pearl L, Workman P. (2003) Assays for HSP90 and inhibitors. In: Novel Anticancer Drug Protocols. Methods in Molecular Medicine, 85 . Humana Press, Totowa, USA, pp. 149-161. ISBN 978-089603963-6

Seddon B, Kelland LR, Workman P. (2003) Bioreductive prodrugs for cancer therapy. In: Methods in Molecular Medicine - Suicide Gene Therapy. Humana Press Inc, Totowa, USA, pp. 515-542. ISBN 978-159259429-0

Garrett MD, Workman P. (2003) Design of drugs targeting the cell cycle. In: Targeted Therapeutics: An Odyssey Tromso Symposium 2003. UNSPECIFIED, Ravnetrykk Tromso, pp. 84-91.

te Poele R, Workman P. (2003) Genomics and drug development. In: Handbook of Anticancer Drug Development. Lippincott Williams & Wilkins, Baltimore, Maryland, pp. 97-116. ISBN 978-078174010-4

Eccles SA. (2003) Invasion and metastasis. In: World Cancer Report. IARC Press, Lyon, France, pp. 119-125. ISBN 978-928320411-4

Schepelmann S, Spooner R, Friedlos F, Marais R. (2003) Methods to improve efficacy in suicide gene therapy approaches: targeting prodrug-activating enzymes carboxypeptidase G2 and nitroreductase to different subcellular compartments. In: Suicide Gene Therapy: Methods and Reviews. Methods in Molecular Medicine . Humana Press Inc, Totowa, New Jersey, Totowa, New Jersey, pp. 279-301. ISBN 978-089603971-1

Springer, C. J., Niculescu-Duvaz, I. (2002) Gene-directed enzyme prodrug therapy. In: AntiCancer Drug Development (Ch. 8). Academic Press, San Diego, USA, pp. 137-155. ISBN 978-012072651-6

Aherne W, Garrett M, McDonald T, Workman P. (2002) Mechanism-based hign-throughput screening for novel anticancer drug discovery. In: AntiCancer Drug Development. Academic Press., New York USA, pp. 249-267. ISBN 978-012072651-6

Eccles SA. (2002) Models for epithelial carcinomas. In: Cancer Handbook. Nature Publishing Group., London, UK, pp. 1081-1100. ISBN 978-033377659-9

Eccles SA (2002) Models for evaluation of targeted therapies of metastatic disease. In: Tumor Models in Cancer Research. Humana Press, Totowa, USA, pp. 293-319. ISBN 978-089603887-5

Workman P. (2002) Novel therapeutic strategies. In: Oxford Handbook of Oncology. Oxford University Press, Oxford, pp. 637-653. ISBN 978-019263035-3

Springer, C. J., Niculescu-Duvaz, I. (2002) Suicide Gene Therapies. In: Encyclopedia of Molecular Medicine. Wiley, pp. 3039-3042.

Eccles SA (2001) Basic Principles for the Study of Metastasis. In: Metastasis Research Protocols: Volume II: Analysis of Cell Behavior In Vitro and In Vivo. Methods in Molecular Medicine, 58 . Humana Press, Totowa, USA, pp. 161-171. ISBN 978-089603615-4

Judson I, Kelland LR. (2001) Cisplatin and analogues. In: Oxford Textbook of Oncology (2nd ed.). Oxford University Press., Oxford, UK, pp. 655-662. ISBN 978-019262926-5

Aherne GW, Garrett M, McDonald E, Workman P (2001) Mechanism-based high throughput screening for novel anticancer drug discovery. In: Anti-cancer Drug Design. Academic Press, London, UK, pp. 249-267.

Eccles SA, O-Charoenrat P. (2001) Mechanisms of metastasis with special reference to squamous cell carcinoma. In: Metastases in Head and Neck Cancer. Proceedings of the 2nd International Symposium. Tectum Verlag, Marburg, Germany, pp. 99-107. ISBN 978-382888254-6

Judson IR, Miller JBG. (2001) Raltitrexed. In: Outline of Oncology Therapeutics. W.B. Saunders Co., Philadelphia, USA, p. 61. ISBN 978-072168123-8

O-Charoenrat P, Rhys-Evans P, Archer D, Eccles SA. (2001) The role of c-erbB receptors in head and neck squamous cell carcinomas: correlation with matrix metalloproteinases and vascular endothelial growth factors. . In: Metastases in Head and Neck Cancer. Proceedings of the 2nd International Symposium. Tectum Verlag, Marburg, Germany, pp. 7-15. ISBN 978-382888254-6

Correction

Niculescu-Duvaz, D., Scanlon, I., Niculescu-Duvaz, I., Springer, C. J. (2006) A higher yielding synthesis of the clinical prodrug ZD2767P using di-protected 4-[N,N-bis(2-hydroxyethyl)aminolphenyl chloroformate (vol 46, pg 6919, 2005). [Correction]

Ahmed, S., James, K., Owen, C. P. (2003) The design, synthesis, and biochemical evaluation of derivatives of biphenyl sulfamate-based compounds as novel inhibitors of estrone sulfatase (vol 294, pg 180, 2002). [Correction]

Editorial

Gronchi, A., Judso, I., Nishida, T., Poveda, A., Martin, J., Reichardt, P., Casali, P. G., Le Cesne, A., Hohenberger, P., Blay, J. Y. (2009) Adjuvant treatment of GIST with imatinib: Solid ground or still quicksand? A comment on behalf of the EORTC Soft Tissue and Bone Sarcoma Group, the Italian Sarcoma Group, the NCRI Sarcoma Clinical Studies Group (UK), the Japanese Study Group on GIST, the French Sarcoma Group and the Spanish Sarcoma Group (GEIS). [Editorial]

de Billy, E., Powers, M. V., Smith, J. R., Workman, P. (2009) Drugging the heat shock factor 1 pathway Exploitation of the critical cancer cell dependence on the guardian of the proteome. [Editorial]

van Montfort, R. L. M., Collins, I. (2009) Fragment-Based Methods in Drug Discovery: It's the Small Things that Matter. [Editorial]

Steeg, P. S., Anderson, R. L., Bar-Eli, M., Chambers, A. F., Eccles, S. A., Hunter, K., Itoh, K., Kang, Y., Matrisian, L. M., Sleeman, J. P., Theodorescu, D., Thompson, E. W., Welch, D. R. (2009) Preclinical Drug Development Must Consider the Impact on Metastasis. [Editorial]

Eccles, S., Irimura, T., Welch, D. (2009) Untitled. [Editorial]

Judson, I. R. (2008) Imatinib for patients with liver or kidney dysfunction: No need to modify the dose. [Editorial]

Judson, I., Barriuso, J. (2008) Molecularly targeted therapy and cancer surgery. [Editorial]

Judson, I. R. (2008) Prognosis, Imatinib Dose, and Benefit of Sunitinib in GIST: Knowing the Genotype. [Editorial]

Workman, P., de Bono, J. (2008) Targeted therapeutics for cancer treatment: major progress towards personalised molecular medicine. [Editorial]

Eccles, S. A. (2007) AACR-NCI-EORTC - 19th symposium - Molecular targets and cancer therapeutics - Part 4 22-26 October 2007, San Francisco, CA, USA. [Editorial]

Workman, P. (2007) Drugging the cancer genome: New challenges of infrequent and combinatorial targets. [Editorial]

Niculescu-Duvaz, D., Whittaker, S., Springer, C., Marais, R. (2007) The EGF receptor Hokey-Cokey. [Editorial]

Workman, P., de Billy, E. (2007) Putting the heat on cancer. [Editorial]

Workman, P., Clarke, P. A., Guillard, S., Raynaud, F. I. (2006) Drugging the PI3 kinome. [Editorial]

Walma, T., Marais, R. (2006) Spotlight on . . . Richard Marais Editor of FEBS Letters since 2001. [Editorial]

Eccles SA, Paon L (2005) Breast cancer metastasis: when, where, how? [Editorial]

Garrett MD, Mittnacht S (2005) Editorial overview: The genetics and biology of cancer - revealing avenues for therapy. [Editorial]

Workman, P., Johnston, P. G. (2005) Genomic profiling of cancer: What next? [Editorial]

Workman P (2005) Genomics and the second golden era of cancer drug development. [Editorial]

Chau, N. M., Ashcroft, M. (2004) Akt2: a role in breast cancer metastasis. [Editorial]

Pestell KE, Workman P (2003) Paul Workman on the challenges of cancer drug development. [Editorial]

Workman P (2003) Preface - Hot topic: Hsp90 Molecular Chaperone Inhibitors: Opportunities and Challenges (Guest Editor: Paul Workman). [Editorial]

Niculescu-Duvaz I (2002) Anti-cancer agents - Preface. [Editorial]

Workman P (2002) Cancer genome targets: Raf-ing up tumour cell to covercome oncogene addiction. [Editorial]

Workman P, Kaye SB (2002) Translating basic cancer research into new cancer therapeutics. [Editorial]

Anderson, H., Price, P., Blomley, M., Leach, M. O., Workman, P. (2001) Measuring changes in human tumour vasculature in response to therapy using functional imaging techniques. [Editorial]

Letter

Yang, J., Ahmed, A., Ashcroft, M. (2009) Activation of a unique p53-dependent DNA damage response. [Letter]

Banerji, U., de Bono, J., Judson, I., Kaye, S., Workman, P. (2008) Biomarkers in early clinical trials: The committed and the skeptics. [Letter]

Carden, C. P., Judson, I. R. (2008) Humors of tumors: Potential for interaction between cancer type and treating oncologist's personality? [Letter]

Molife, R., Fong, P., Scurr, M., Judson, I., Kaye, S., de Bono, J. (2007) HDAC inhibitors and cardiac safety. [Letter]

Liu WM, Baird R, Sarker D, Powles T (2005) Antiapoptotic effect of growth factors in leukemia. [Letter]

Neuhaus SJ, Clark MA, Thomas JM, Judson I (2004) Gastrointestinal stromal tumours (Br J Surg 2003; 90 : 1178-1186). [Letter]

Judson I (2004) In relation to Anninga et al Overexpression of the HER-2 oncogene does not play a role in high-grade osteosarcomas. [Letter]

Kumar P, Ladas GP, Judson I, Nicholson AG (2003) Epithelioid hemangioendothelioma and other vascular mediastinal tumors: A role for alpha-2a interferon? [Letter]

Andreyev, H. J. N., Benamouzig, R., Beranek, M., Clarke, P., Cunningham, D., Norman, A. R., Giaretti, W., de Goeij, A. F. P. M., Iacopetta, B. J,. Jullian, E., Krtolica, K., Lee, J. Q., Wang, S. T., Lees, N., Al-Mulla, F., Muller, O., Pauly, M., Pricolo, V., Russo, A., Troungos, C., Urosevic, N., Ward, R. (2003) Mutant K-ras2 in serum. [Letter]

Grayson, C., Chapple, J. P., Willison, K. R., Webster, A. R., Hardcastle, A. J., Cheetham, M. E. (2002) In vitro analysis of aminoglycoside therapy for the Arg 120stop nonsense mutation in RP2 patients. [Letter]

Review Article

Carden, C. P., Sarker, D., Postel-Vinay, S., Yap, T. A., Attard, G., Banerji, U., Garrett, M. D., Thomas, G. V., Workman, P., Kaye, S. B., de Bono, J. S. (2010) Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development? DRUG DISCOVERY TODAY, 15 (3—4). pp. 406-420. ISSN 1359-6446

Krikelis, D., Judson, I. (2010) Role of chemotherapy in the management of soft tissue sarcomas. EXPERT REVIEW OF ANTICANCER THERAPY, 10 (2). pp. 249-260. ISSN 1473-7140

Naylor, A. M., Pojasek, K. R., Hopkins, A. L., Blagg, J. (2010) The tetrahydrobiopterin pathway and pain. CURRENT OPINION IN INVESTIGATIONAL DRUGS, 11 (1). pp. 19-30. ISSN 1472-4472

Tan, D. S. W., Thomas, G. V., Garrett, M. D., Banerji, U., de Bono, J. S., Kaye, S. B., Workman, P. (2009) Biomarker-Driven Early Clinical Trials in Oncology A Paradigm Shift in Drug Development. CANCER JOURNAL, 15 (5). pp. 406-420. ISSN 1528-9117

Davies, T. G., Woodhead, S. J., Collins, I. (2009) Fragment-Based Discovery of Inhibitors of Protein Kinase B. CURRENT TOPICS IN MEDICINAL CHEMISTRY, 9 (18). pp. 1705-1717. ISSN 1568-0266

Price, D. A., Blagg, J., Jones, L., Greene, N., Wager, T. (2009) Physicochemical drug properties associated with in vivo toxicological outcomes: a review. EXPERT OPINION ON DRUG METABOLISM, 5 (8). pp. 921-931. ISSN 1742-5255

van Montfort, R. L. M., Workman, P. (2009) Structure-based design of molecular cancer therapeutics. TRENDS IN BIOTECHNOLOGY, 27 (5). pp. 315-328. ISSN 0167-7799

Collins, I. (2009) Targeted Small-Molecule Inhibitors of Protein Kinase B as Anticancer Agents. ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 9 (1). pp. 32-50. ISSN 1871-5206

Smith, J. R., Workman, P. (2009) Targeting CDC37 An alternative, kinase-directed strategy for disruption of oncogenic chaperoning. CELL CYCLE, 8 (3). pp. 362-372. ISSN 1538-4101

Pearl, L. H., Prodromou, C., Workman, P. (2008) The Hsp90 molecular chaperone: an open and shut case for treatment. BIOCHEMICAL JOURNAL, 410 (Part 3). pp. 439-453. ISSN 0264-6021

Yap, T. A., Garrett, M. D., Walton, M. I., Raynaud, F., de Bono, J. S., Workman, P. (2008) Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises. CURRENT OPINION IN PHARMACOLOGY, 8 (4). pp. 393-412. ISSN 1471-4892

Smith, N. F., Raynaud, F. I., Workman, P. (2007) The application of cassette dosing for pharmacokinetic screening in small-molecule cancer drug discovery. MOLECULAR CANCER THERAPEUTICS, 6 (2). pp. 428-440. ISSN 1535-7163

Hedley, D., Ogilvie, L., Springer, C. (2007) Carboxypeptidase G2-based gene-directed enzyme-prodrug therapy: a new weapon in the GDEPT armoury. NATURE REVIEWS CANCER, 7 (11). pp. 870-879. ISSN 1474-175X

Antoni, L., Sodha, N., Collins, I., Garrett, M. D. (2007) CHK2 kinase: cancer susceptibility and cancer therapy - two sides of the same coin? NATURE REVIEWS CANCER, 7 (12). pp. 925-936. ISSN 1474-175X

Powers, M. V., Workman, P. (2007) Inhibitors of the heat shock response: Biology and pharmacology. FEBS LETTERS, 581 (19). pp. 3758-3769. ISSN 0014-5793

Eccles, S., Paon, L., Sleeman, J. (2007) Lymphatic metastasis in breast cancer: importance and new insights into cellular and molecular mechanisms. CLINICAL & EXPERIMENTAL METASTASIS, 24 (8). pp. 619-636. ISSN 0262-0898

Gray-Schopfer, V., Wellbrock, C., Marais, R. (2007) Melanoma biology and new targeted therapy. NATURE, 445 (7130). pp. 851-857. ISSN 0028-0836

Eccles, S. A., Welch, D. R. (2007) Metastasis: recent discoveries and novel treatment strategies. LANCET, 369 (9574). pp. 1742-1757. ISSN 0140-6736

Sarker, D., Workman, P. (2007) Pharmacodynamic biomarkers for molecular cancer therapeutics. ADVANCES IN CANCER RESEARCH, 96 . pp. 213-268. ISSN 0065-230X

McErlean, C. S. P., Proisy, N., Davis, C. J., Boland, N. A., Sharp, S. Y., Boxall, K., Slawin, A. M. Z., Workman, P., Moody, C. J. (2007) Synthetic ansamycins prepared by a ring-expanding Claisen rearrangement. Synthesis and biological evaluation of ring and conformational analogues of the Hsp90 molecular chaperone inhibitor geldanamycin. ORGANIC & BIOMOLECULAR CHEMISTRY, 5 (3). pp. 531-546. ISSN 1477-0520

Sarker, D., Pacey, S., Workman, P. (2007) Use of pharmacokinetic/pharmacodynamic biomarkers to support rational cancer drug development. BIOMARKERS IN MEDICINE, 1 (3). pp. 399-417. ISSN 1752-0363

Collins, I., Workman, P. (2006) Design and development of signal transduction inhibitors for cancer treatment: Experience and challenges with kinase targets. CURRENT SIGNAL TRANSDUCTION THERAPY, 1 (1). pp. 13-23. ISSN 1574-3624

McDonald, E., Jones, K., Brough, P. A., Drysdale, M. J., Workman, P. (2006) Discovery and development of pyrazole-scaffold Hsp90 inhibitors. CURRENT TOPICS IN MEDICINAL CHEMISTRY, 6 (11). pp. 1193-1203. ISSN 1568-0266

Attard, G., Sarker, D., Reid, A., Molife, R., Parker, C., de Bono, J. S. (2006) Improving the outcome of patients with castration-resistant prostate cancer through rational drug development. BRITISH JOURNAL OF CANCER, 95 (7). pp. 767-774. ISSN 0007-0920

McDonald, E., Workman, P., Jones, K. (2006) Inhibitors of the HSP90 molecular chaperone: Attacking the master regulator in cancer. CURRENT TOPICS IN MEDICINAL CHEMISTRY, 6 (11). pp. 1091-1107. ISSN 1568-0266

Workman, P., Aboagye, E. O., Chung, Y. L., Griffiths, J. R., Hart, R., Leach, M. O., Maxwell, R. J., McSheehy, P. M. J., Price, P. M., Zweit, J., Canc Res UK Pharmacodynamic Pharma, [Group Author] (2006) Minimally invasive pharmacokinetic and pharmacodynamic technologies in hypothesis-testing clinical trials of innovative therapies. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 98 (9). pp. 580-598. ISSN 0027-8874

Collins, I., Workman, P. (2006) New approaches to molecular cancer therapeutics. NATURE CHEMICAL BIOLOGY, 2 (12). pp. 689-700. ISSN 1552-4450

Schepelmann, S., Springer, C. J. (2006) Viral vectors for gene-directed enzyme prodrug therapy. CURRENT GENE THERAPY, 6 (6). pp. 647-670. ISSN 1566-5232

Rogers SJ, Harrington KJ, Rhys-Evans P, Charoenrat PO, Eccles SA (2005) Biological significance of c-erbB family oncogenes in head and neck cancer. CANCER AND METASTASIS REVIEWS, 24 (1). pp. 47-69. ISSN 0167-7659

Eccles SA, Box C, Court W (2005) Cell migration/invasion assays and their application in cancer drug discovery. BIOTECHNOLOGY ANNUAL REVIEW, 11 . pp. 391-421. ISSN 1387-2656

Benson, C., Kaye, S., Workman, P., Garrett, M., Walton, M., de Bono, J. (2005) Clinical anticancer drug development: targeting the cyclin-dependent kinases. BRITISH JOURNAL OF CANCER, 92 (1). pp. 7-12. ISSN 0007-0920

Blagden S, de Bono J (2005) Drugging cell cycle kinases in cancer therapy. CURRENT DRUG TARGETS, 6 (3). pp. 325-335. ISSN 1389-4501

Kristeleit R, Fong P, Aherne GW, de Bono J (2005) Histone deacetylase inhibitors: Emerging anticancer therapeutic agents? CLINICAL LUNG CANCER, 7 (Supplement 1). S19-S30. ISSN 1525-7304

Niculescu-Duvaz, I., Springer, C. J. (2005) Introduction to the background, principles, and state of the art in suicide gene therapy. MOLECULAR BIOTECHNOLOGY, 30 (1). pp. 71-88. ISSN 1073-6085

Vidal L, Blagden S, Attard G, de Bono J (2005) Making sense of antisense. EUROPEAN JOURNAL OF CANCER, 41 (18). pp. 2812-2818. ISSN 0959-8049

Bardos JI, Ashcroft M (2005) Negative and positive regulation of HIF-1: A complex network. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 1755 (2). pp. 107-120. ISSN 0304-419X

Rogers SJ, Box C, Harrington KJ, Nutting C, Rhys-Evans P, Eccles SA (2005) The phosphoinositide 3-kinase signalling pathway as a therapeutic target in squamous cell carcinoma of the head and neck. EXPERT OPINION ON THERAPEUTIC TARGETS, 9 (4). pp. 769-790. ISSN 1472-8222

Neuhaus SJ, Clark MA, Hayes AJ, Thomas JM, Judson I (2005) Surgery for gastrointestinal stromal tumour in the post-imatinib era. ANZ JOURNAL OF SURGERY, 75 (3). pp. 165-172. ISSN 1445-1433

Eccles SA (2005) Targeting key steps in metastatic tumour progression. CURRENT OPINION IN GENETICS & DEVELOPMENT, 15 (1). pp. 77-86. ISSN 0959-437X

Carroll V and Ashcroft M (2005) Targeting the molecular basis for tumour hypoxia. EXPERT REVIEW IN MOLECULAR MEDICINE, 7 (6). pp. 1-16. ISSN 1462-3994

Clarke PA, te Poele R, Workman P (2004) Gene expression microarray technologies in the development of new therapeutic agents. EUROPEAN JOURNAL OF CANCER, 40 (17). pp. 2560-2591. ISSN 0959-8049

Bardos JI, Ashcroft M (2004) Hypoxia-inducible factor-1 and oncogenic signalling. BIOESSAYS, 26 (3). pp. 262-269. ISSN 0265-9247

Dymock BW, Drysdale MJ, McDonald E, Workman P (2004) Inhibitors of HSP90 and other chaperones for the treatment of cancer. EXPERT OPINION ON THERAPEUTIC PATENTS, 14 (6). pp. 837-847. ISSN 1354-3776

Brader S, Eccles SA (2004) Phosphoinositide 3-kinase signalling pathways in tumor progression, invasion and angiogenesis. TUMORI - A JOURNAL OF EXPERIMENTAL AND CLINICAL ONCOLOGY, 90 (1). pp. 2-8. ISSN 0300-8916

Eisenberg, B. L., Judson, I. (2004) Surgery and imatinib in the management of GIST: Emerging approaches to adjuvant and neoadjuvant therapy. ANNALS OF SURGICAL ONCOLOGY, 11 (5). pp. 465-475. ISSN 1068-9265

Workman, P. (2003) Auditing the pharmacological accounts for Hsp90 molecular chaperone inhibitors: Unfolding the relationship between pharmacokinetics and pharmacodynamics. MOLECULAR CANCER THERAPEUTICS, 2 (2). pp. 131-138. ISSN 1535-7163

Banerji, U., Judson, I., Workman, P. (2003) The clinical applications of heat shock protein inhibitors in cancer - present and future. CURRENT CANCER DRUG TARGETS, 3 (5). pp. 385-390. ISSN 1568-0096

Baird RD, Kaye SB (2003) Drug resistance reversal - are we getting closer? EUROPEAN JOURNAL OF CANCER, 39 (17). pp. 2450-2461. ISSN 0959-8049

Scanlon, I., Lehouritis, P., Niculescu-Duvaz, I., Marais, R., Springer, C. J. (2003) Gene regulation in cancer gene therapy strategies. CURRENT MEDICINAL CHEMISTRY, 10 (20). pp. 2175-2184. ISSN 0929-8673

Workman P (2003) The opportunities and challenges of personalized genome-based molecular therapies for cancer: targets, technologies, and molecular chaperones. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 52 (Supplement 1). S45-S56. ISSN 0344-5704

Workman P (2003) Strategies for treating cancers caused by multiple genome abnormalities. From concepts to cures? CURRENT OPINION IN INVESTIGATIONAL DRUGS (LONDON, ENGLAND: 2000), 4 (12). pp. 1410-1415. ISSN 1472-4472

Katan M, Rodriguez R, Matsuda M, Newbatt YM, Aherne GW (2003) Structural and mechanistic aspects of phospholipase C gamma regulation. ADVANCES IN ENZYME REGULATION, 43 . pp. 77-85. ISSN 0065-2571

Niculescu-Duvaz, D., Heyes, J., Springer, C. J. (2003) Structure-activity relationship in cationic lipid mediated gene transfection. CURRENT MEDICINAL CHEMISTRY, 10 (14). pp. 1233-1261. ISSN 0929-8673

Kudrin AV, Gromova OA (2003) Two faces of zinc in the brain. TRACE ELEMENTS AND ELECTROLYTES, 20 (1). pp. 1-4. ISSN 0946-2104

Brock, C. S., Lee, S. M. (2002) Anti-angiogenic strategies and vascular targeting in the treatment of lung cancer. EUROPEAN RESPIRATORY JOURNAL, 19 (3). pp. 557-570. ISSN 0903-1936

Kirn, D., Niculescu-Duvaz, I., Hallden, G., Springer, C. J. (2002) The emerging fields of suicide gene therapy and virotherapy. TRENDS IN MOLECULAR MEDICINE, 8 (Supplement 4). S68-S73. ISSN 1471-4914

Judson, I. (2002) Gastrointestinal stromal tumours (GIST): biology and treatment. ANNALS OF ONCOLOGY, 13 (Supplement 4). pp. 287-289. ISSN 0923-7534

Maloney A, Workman P (2002) HSP90 as a new therapeutic target for cancer therapy: the story unfolds. EXPERT OPINION ON BIOLOGICAL THERAPY, 2 (1). pp. 3-24. ISSN 1471-2598

Workman, P. (2002) The impact of genomic and proteomic technologies on the development of new cancer drugs. ANNALS OF ONCOLOGY, 13 (Supplement 4). pp. 115-124. ISSN 0923-7534

Workman P, Clarke PA (2001) Innovative cancer drug targets: genomics, transcriptomics and clinomics. EXPERT OPINION ON PHARMACOTHERAPY, 2 (6). pp. 911-915. ISSN 1465-6566

Eccles, S. A. (2001) Monoclonal antibodies targeting cancer: 'magic bullets' or just the trigger? BREAST CANCER RESEARCH, 3 (2). pp. 86-90. ISSN 1465-542X

Workman P (2001) New drug targets for genomic cancer therapy: successes, limitations, opportunities and future challenges. CURRENT CANCER DRUG TARGETS, 1 (1). pp. 33-47. ISSN 1568-0096

Workman P (2001) Overview. Changing times: developing cancer drugs in genomeland. CURRENT OPINION IN INVESTIGATIONAL DRUGS (LONDON, ENGLAND: 2000), 2 (8). pp. 1128-1135. ISSN 1472-4472

Workman P (2001) Scoring a bull's-eye against cancer genome targets. CURRENT OPINION IN PHARMACOLOGY, 1 (4). pp. 342-352. ISSN 1471-4892